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Human immunodeficiency virus-1 (HIV-1)-associated neurocognitive disorder (HAND) 
is a subcortical disease involving neuronal loss and myelin damage. Myelin is deposited 
by oligodendrocytes through a complex process including oligodendrocyte progenitor 
cell (OPC) proliferation and maturation. Oligodendrocytes/OPCs are susceptible to viral 
proteins such as Tat and that myelin damage is associated with oligodendrocyte number 
decrease. It has been shown that activation of voltage-gated K+ (KV) channels mediates 
apoptosis in various cell types. KV1.3 is the most predominant KV channel expressed in 
OPCs/oligodendrocytes and potentially involved in OPC developmental regulation. We 
studied the involvement of KV1.3 in Tat-induced OPC/oligodendrocyte injury and OPC 
maturation deficit. Tat increased KV1.3 currents in cultured OPCs and oligodendrocytes 
may through direct interaction and interrupting channel phosphorylating regulation, 
leading to OPC maturation retardation and OPC/oligodendrocyte apoptosis. Tat-caused 
myelin injury was validated in corpus callosum and striatum of cultured rat brain slices. 
These effects were prevented by KV1.3 antagonists or KV1.3-siRNA knockdown.  
Gelsolin (GSN), an actin-binding protein best-known for its modulation of cell motility 
and secretion. Neurons appear to be a major source of GSN in CNS and GSN-null 
neurons have enhanced cell death. The GSN level is decreased in CSF of HIV-1-
infected individuals. Studies have demonstrated that enhancement of KV currents results 




injury in HAND, we studied the effects of GSN on HIV-1 glycoprotein 120 (gp120)-
activated outward K+ currents in primary rat cortical neuronal cultures. Gp120 enhanced 
outward K+ and resulted in neuronal apoptosis. GSN suppressed the gp120-induced 
outward K+ current increase and reduced vulnerability to gp120-induced neuronal 
apoptosis. The GSN-mediated suppression of gp120 enhancement of neuronal outward 
K+ current was blocked by KV2.1 inhibitor. In parallel, gp120 up-regulated KV2.1 channel 
expression, which was also blocked by GSN.  
Taken together, my thesis research demonstrates that Tat induces myelin damage 
by KV1.3-mediated OPC/oligodendrocyte injury and maturation defects, which may have 
implications for the pathogenesis of HAND. GSN protects neurons from gp120-
associated changes by suppression of gp120-induced enhancement of KV2.1 K
+ currents, 
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Chapter 1 Introduction 
 
Review of HIV-1-associated Neurocognitive 
disorder, neurons, oligodendrocyte, and K
+
 






Oligodendrocytes wrap neuronal axons to form myelin, which is an insulating sheath 
essential for the electrical saltatory conduction along axons. The process of myelination 
is highly regulated by neuronal and astrocytic signals and, maintenance of myelin 
sheaths is a very complex process. Oligodendrocyte injury results in demyelination and 
further neurological dysfunction. Demyelination in cerebrum may cause cognitive 
impairment in a broad array of diseases including human immunodeficiency virus type 
one (HIV-1)-associated neurocognitive disorder (HAND). Although the combined 
antiretroviral therapy has markedly reduced HIV-1 incidence of HIV-1-associated 
dementia, which is a severe form of HAND, milder forms of HAND remain prevalent 
even when viral load in blood is well controlled. HAND manifests as a subcortical 
dementia involving subcortical damage in white matter (e.g., corpus callosum), which 
mostly consists of myelinated axonal fibers. How HIV-1 brain infection causes myelin 
injury and resultant white matter damage is an interesting area of current HIV-1 
neurology research. In this Chapter, we tentatively address recent progresses on 
oligodendrocyte dysregulation and HAND pathogenesis. 




Although combination antiretroviral therapy (cART) has markedly reduced human 
immunodeficiency virus type one (HIV-1)-associated mortality, HIV-1-associated 
neurocognitive disorders (HAND) remains prevalent [1-3]. More than 50% of HIV-1 
positive individuals have central nervous system (CNS) syndromes, involving subcortical 
damage in white matter (WM, e.g., corpus callosum) and/or deep grey matter [4-8]. HIV-
1-related WM damage includes demyelination and axonal dysfunction and/or damage. 
Demyelination is when myelin sheath of neuronal axons, which enables rapid and 
efficient saltatory conduction, is impaired in the CNS or peripheral nervous system 
(PNS). Myelination, formation of myelin sheaths by oligodendrocytes wrapping neuronal 
axons in the CNS or Schwann cells in the PNS, is highly regulated by neuronal and 
astrocytic signals and, maintenance of myelin sheaths is a very complex process. 
Oligodendrocyte injury is the hallmarks of demyelination and WM damage. 
Oligodendrocyte injury can be induced by genetics, viral proteins, inflammation, 
autoimmune response and other unknown factors. HIV-1-related oligodendrocyte/myelin 
injury has been reported both in cell culture [9] and patients [10]. 
Earlier studies demonstrate that human polyomavirus JC (JCV) primarily causes 
demyelination in HIV-1-infected brain. Compared to HIV-1 infection of astrocytes and 
microglia in brain, JCV predominately infects oligodendrocytes and thus cause 
oligodendrocyte loss and demyelination. JCV is the main causative of progressive 
multifocal leukoencephalopathy (PML), a frequent opportunistic infection in the CNS and 
a common complication seen in AIDS patients [10, 11]. Recently, several research 
groups have reported that HIV-1 and viral proteins per se can target at oligodendrocytes 
and cause the detrimental effects, which are JCV-independent [9, 12, 13]. HIV-1 viral 
proteins, including the envelope glycoprotein gp120, trans-activator of transcription (Tat), 
and negative regulatory factor (Nef), have been implicated in oligodendrocyte toxicity [12, 
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14-17]. Among these proteins, Tat has been detected in both infected and uninfected 
oligodendrocytes in the brains of AIDS patients [10], and showed synergistic effect with 
JCV or addictive drug as morphine. The myelin injury-related milder neurocognitive 
disorders and the oligodendrocyte pathogenesis in HAND are attracting attention of 
neurovirologists worldwide.  
1. Overview of HAND 
HIV includes two types, HIV type 1 and 2 (HIV-1, 2). There is limited knowledge 
about HIV-2, which has not been commonly seen outside of Africa. Thus all of the 
diseases mentioned in this dissertation are HIV-1 associated. HIV-1 primarily infects 
CD4+ T cells and monocyte/macrophage lineage cells. HIV enters cells by interacting 
with CD4 receptor and two co-receptors, CXCR4 or CCR5.  
Infected monocytes or macrophages traverse blood brain barrier (BBB) to invade 
brain. The invasion of HIV-1 happens in the early stage of primary infection. Invaded 
viruses replicate in brain, causing inflammatory and neurotoxic effects that contribute to 
cognitive, behavioral and motor function deficits. This progressive neurologic disease is 
clinically characterized by cognitive deficits in patients with HIV-1 infection [18]. 
1.1. HAND clinical diagnosis 
HAND is divided to three categories depending on degree of severity: asymptomatic 
neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-1-
associated dementia (HAD). The detailed current diagnostic criteria for HAND are 
published on AIDS education and Training Centers National Coordinating Resource 
Center (http://aidsetc.org/guide/hiv-associated-neurocognitive-disorders). Patients 
accept standardized neuropsychological survey (e.g. learning function, construction, 
memory registration, attention, concentration) and are diagnosed by a combination of 
dementia scale, day-to-day functioning interference, and no pre-existing cause of 
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cognitive deficits [1, 19-21]. However, the impairments in ANI and MND may escape 
clinical diagnosis. HAD patients undergo marked neuron interference with daily 
functioning, acquire cognitive impairments particularly in the new information registration, 
information processing and attention/concentration deficits [20-22].  
1.2. Overview of HAND neuropathogenesis 
Obviously, HAND symptoms are closely attribute to neuronal dysfunction or/and loss. 
However, HIV-1 does not infect neurons directly. The mainly proposed mechanisms 
leading to HAND involve infected macrophages, microglia, or astrocytes secreting 
neurotoxins resultant in neuronal function alterations and death. Viral proteins (e.g. 
gp120, Tat, Nef, Vpr), arachidonic acid, free radicals (NO. and O2
.-), glutamate, 
quinolinate, cysteine, cytokines (e.g., CCL12, IL-1β, TNF-α), and amines have been 
reported that act as neurotoxins in HAND [23]. These toxic factors generally act through 
two proposed models: direct model and indirect model. The direct model offers 
hypothesis that viral proteins released from infected cells manifest direct cytotoxicity on 
neurons [24]. The indirect model proposes that the neuronal death or dysfunction is 
consequently mediated by inflammatory response designedly against HIV-1 infection or 
viral proteins [24, 25]. The HIV-1 infection-caused processes alter neuronal function and 
survivals have been extensively addressed. In the pre-cART era, inflammation and 
neurodegeneration were believed as the predominant pathogenesis drive HAND 
progression [26]. However, emerging evidences demonstrate the direct actions of viral 
proteins may take the major place particularly in these patients with good access of 
cART [27, 28].  
2. Overview of oligodendrocytes 
In the CNS, oligodendrocyte plasma membrane processes enclose axons leading to 
formation of myelin sheath, which is essential for fast axonal conduction. Myelinated 
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axons appear myelin-dependency during development, thus demyelination can lead to 
progressive decline in these axons [29]. Neuronal conduction deficits in HAND patients 
can be attribute to primary neuron injury or consequent injury caused by myelin 
dysfunction/loss, suggesting disruption of oligodendrocyte function my contribute to 
HAND progression [27]. Oligodendrocytes rise from oligodendrocyte progenitor cells 
(OPCs) or neural stem/progenitor cells (NPCs). These two populations are capable to 
generate new oligodendrocytes in response to myelin injury to maintain myelin function. 
[30]. As OPCs are the major proliferating cell population within the adult CNS, they have 
the most capacity to re-form myelin sheath. Thus, OPC proliferation, differentiation and 
maturation are critical processes for axonal remyelination. It has been shown that 
differentiation of OPCs into oligodendrocyte is greatly challenging during remyelination 
[31, 32]. OPC differentiation is controlled by a number of factors, many of which act to 
inhibit myelination, including Leucine-rich repeat and immunoglobulin domain-
containing-1 (LINGO-1) [33, 34], Notch-1 [35, 36], Wnt [37] etc. Whereas, p38 MAPK [38, 
39] and AKT [40] have been shown to be required for oligodendrocyte differentiation and 
myelination. 
3. Myelin/oligodendrocyte injury in HIV-1 patients  
The oligodendrocyte and myelin injury have been observed clinically from 
neurological imaging studies, serum biochemistry and brain biopsies [6, 8, 41, 42]. The 
diffusion tensor magnetic resonance imaging (DTI) promotes the investigations of WM 
damage in early HAND and, allows revealing the microstructures of myelin and 
oligodendrocytes. The changes of water molecules diffusive parameters in brain WM of 
HIV-1 patient, which indicate demyelination, have been detected in several DTI studies 
[6, 43, 44]. These findings were supported by a recent study in HIV-1-infected 
humanized mice that the decreased expression myelin structural proteins were observed 
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in whisker barrels, corpus callosum, and hippocampus, suggesting the loss of myelin 
elements [45]. In the serum and CSF of patients with HAND, antibody titers of myelin 
oligodendrocyte glycoprotein (MOG), an important myelin structural protein indicating 
CNS-specific autoimmune reaction for primary demyelination, are significantly higher 
compared with asymptomatic HAND patients and HIV-1-negative patients with other 
neurological disease. In particular, CSF anti-MOG antibodies exhibit a high sensitivity 
and specificity (85.7% and 76.2%) in those patients with active HAND. The 
performances on HIV dementia scale test are significantly worse and the viral loads in 
CSF are higher in MOG immunopositive HAND patients than those in asymptomatic 
HAND patients [46], suggesting the dysfunction of oligodendrocyte is closely related with 
HIV-1 infection and HAND.  
Compared to astrocytes that tend to promote recovery in response to injury, 
oligodendrocytes are more susceptible and appear to be damaged as a general 
response to insults [47]. In biopsy studies, the significant loss of nerve fibers and axons 
are observed in HIV-1-infected brain, in particular in the frontal and occipital parts of the 
corpus callosum. The myelin sheath thickness diminishes in corpus callosum as well [8]. 
Weighted gene co-expression network analysis showed an increase of oligodendrocyte-
related genes particularly in the HIV encephalitis (HIVE) group, suggesting specific 
dysfunction of oligodendrocyte in HIVE [48]. 
In those HIV-1 positive patients with PML, the myelin loss is apparent both 
macroscopically and microscopically [49]. Neuroimaging studies show the myelin lesions 
are more frequently seen in the sub-cortical WM areas [50]. PML is believed to be 
developed exclusively in immunosuppressive patients with significantly higher incidence 
in patients with AIDS, particularly in AIDS patients without cART and with a low 
lymphocyte CD4+ count, than in patients with any other immunosuppressive conditions. 
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Although cART has decreased the incidence of PML and improved the patient survival 
[51], PML was recently reported that occurred in HIV-1-positive patients with good 
access of cART and even with normal CD4+ lymphocyte level [52, 53]. These findings 
suggest PML-related oligodendrocyte/myelin damage is often, but not necessarily, 
associated with severe immunosuppression or an immune reconstitution inflammatory 
syndrome (IRIS) in pathogenesis of cART era HIV neurology (neuroHIV) [54].  
4. Fate of oligodendrocytes in HIV-1-infected brain 
Early publications reported that HIV-1 cannot be detected in oligodendrocytes [55, 
56], may due to the limitations of methodology to identify oligodendrocytes. Dissenting 
result was found in purified human oligodendrocytes from temporal lobe resections, HIV-
1 (IIIB and BaL) infectivity was confirmed by detection of p24gag antigen and PCR 
amplification [57]. It is well-known that HIV-1 attaches and infects human host cells 
through CD4 receptor, along with CXCR4 and CCR5 as co-receptors. Oligodendrocytes 
are CD4 and CCR5 negative but do express CXCR4 [28, 55, 58], which designedly 
promote the OPC migration and remyelination [59], may provide the anchor for HIV-1-
induced oligodendrocyte toxicity. However, most investigators agree that HIV-1 primarily 
infects microglial cells of the brain but oligodendrocyte is not the main target. HIV-1-
associated oligodendrocyte injury is believed to be mediated through viral proteins shed 
from viruses released from infected other cells [12, 14, 15].  
In HIV-1 patients with PML complication, Tat and JCV are both present in 
oligodendrocytes. Tat has been shown to synergize with JCV, and facilitate of JCV gene 
transcription and replication, leading to robust JCV infection [60, 61]. Tat stimulates JCV 
gene transcription by cooperating with SMAD proteins, the intracellular effectors of TGF-
beta, at the JCV DNA control region (Fig. 1A) [60]. The effectiveness of Tat on 
facilitating JCV transcription and replication varies from different HIV clades [61]. 
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Because Tat can continuously exist in brain while the viral load is controlled in blood, this 
may partially explain the cases that HIV-1 patients develop PML even with good access 
of cART [62]. Besides the synergistic effect of Tat and JCV in oligodendrocytes, 
cytotoxic CD8+ T cells aggregate at demyelinated lesions in brain to engage JCV-
infected oligodendrocytes, which tends to control JCV dissemination but at the cost of 
oligodendrocyte death and further demyelination in PML [63]. 
In addition to Tat, gp120 seems to involve in HIV-1-associated 
oligodendrocytes/myelin injury as well. It has been shown that gp120 inhibits myelination 
in rat cerebral cortex culture [14] and to induce functional dysregulation and apoptosis in 
cultured oligodendrocytes [15, 64], which is discussed in subsequent section. The 
primary oligodendrocyte injury, which leads to secondary axonal injury (outside-in) to 
further exacerbate neurocognitive impairments, oligodendrocyte injury can be caused by 
primary axonopathy as well (inside-out) [65]. The recent study has shown that gp120-
induced β-APP accumulation and axon injury in corpus callosum was attenuated by a 
CXCR4 antagonist, exampling HIV-1 injury of oligodendrocyte/myelin injury via CXCR4 
receptors [28]. Although it is not clear whether gp120 cause such a detrimental effect 
through “outside-in” or “inside-out” mechanism or both, CXCR4 expressed on 
oligodendrocytes can be a potential target [65].  
5. Association between BBB disruption and myelin deficits 
Increasing evidences indicate that myelin injury may be associated with dysregulated 
BBB since WM pallor is often observed in perivascular sectors [66] [67]. BBB is a 
critically protective barrier for the brain. It serves as a highly selective layer that separate 
CNS from the rest of the body. HIV-1-related BBB alteration is attributed to 
proinflammatory cytokine secretion, released viral proteins from infected cells, and HIV-1 
infection of endothelial cells [68, 69]. The reported direct mechanisms are often related 
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to alterations of vascular tight junctions, direct toxicity of brain endothelial cells, 
production of matrix metalloproteinase, and NMDA receptor activation [70, 71]. The 
disruption of BBB is believed essential for HIV-1 to access to brain. In another hand, 
BBB alteration per se may also underlie neurologic deficits in neuroHIV patients. This is 
supported by an observation that HIV-1 patients with impaired BBB showed poorer 
neurologic status than those with intact BBB [72]. However, myelin damage may be 
related to BBB disruption without HIV-1 brain invasion. In a case report, diffuse myelin 
pallor in WM and massive perivascular dilatation were observed in an AIDS patient 
without evidence of brain HIV infection, significant inflammation, or microglial activation 
[73]. Postmortem studies on AIDS patients brains showed that the discrete myelin pallor 
areas are always associated with capillaries or venules [67]. These findings suggest that 
BBB breakdown caused diffuse leak and other circulating factors may contribute to the 
observed myelin pathogenesis.  
Under physiological conditions, the BBB endothelial cells and components of the 
extracellular matrix support OPC survival, and promote NPC differentiate to neurons, 
astrocytes and oligodendrocytes [74-76]. The critical function of BBB and the 
consequences of BBB alteration imply the contributions of BBB disruption in HIV-1-
associtated oligodendrocyte/myelin injury. It is not surprising the BBB disruption will 
result in enhanced entrance of free virus, infected T cells, and toxic components from 
blood. It has been reported that OPC proliferation can be reduced by plasma, serum, 
thrombin and plasmin in primary culture. Thrombin also suppresses the differentiation of 
OPCs into mature oligodendrocytes [77]. In addition, the expression level of TNF-α is 
elevated in blood mononuclear cells of HIV-infected patients [78], of which TNF-α is 
demonstrated that promoting oligodendrocyte death [79]. HIV-1 infection also induces 
interleukin (IL)-1β production in human monocytes [80], of which IL-1β can promote 
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oligodendrocyte death through glutamate excitotoxicity [81]. These findings provide 
potential mechanisms of BBB disruption contribution to HIV-1-associated 
myelin/oligodendrocyte damage. 
6. Cellular mechanisms of oligodendrocyte loss in HIV-1-infected brain 
Apoptosis of oligodendrocytes has been demonstrated in HAND patients. 
Accumulating evidences indicate that HIV-1 viral proteins can injure oligodendrocytes 
directly or through a comorbid effect with addictive drugs. 
It is well-known that tumor suppressor p53 induce apoptosis by activating 
transcription of various pro-apoptotic genes [82]. Activation of p53 is detected in the 
oligodendrocyte lineage cells in the brain of HAND patients, which cannot be detected in 
control brains [83]. Because of difficulties to distinguish differentiating stages of 
oligodendrocyte lineage on autopsy samples, the detected p53 reactivity reflects 
apoptosis of mature oligodendrocytes (Fig. 1B) and OPCs. This suggests that in addition 
to oligodendrocyte injury, proliferation of OPCs may be also impaired in HAND.  
Gp120 causes slow but progressive oligodendrocyte cytosolic Ca2+ rise in a mixed 
culture of cerebellar cortex cells [64], which is a potential apoptotic cause. Exposure of 
oligodendrocytes to Tat also triggers rapid increase in intracellular Ca2+ level through 
targeting at NMDA and AMPA receptors thus cause consequent oligodendrocyte injury. 
It is worth to mention that the roles of NMDA and AMPA receptors appear to be different 
and dependent on the stage of OPC differentiation [9]. Our data suggest that Tat can 
cause oligodendrocyte apoptosis in vitro and myelin loss ex vivo by enhancing voltage-
dependent K+ channel (KV) 1.3 activity (Chapter 2). The efflux of K
+ ions causes the cell 
shrinkage leading to apoptotic cell volume decrease and eventual apoptosis (Fig. 1B) 
[84]. Oligodendrocytes within the striatum are highly sensitive to the effects of morphine 
in HIV-1 Tat transgenic mice [12]. Striatal oligodendrocytes are the only apoptotic cell 
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type in response to combined morphine exposure and Tat induction in the Tat transgenic 
mice [12]. Tat also interacts with morphine to decrease the proliferation of OPCs [85]. 
Opioid abuse causes synergistic toxicity in HIV-1-associated pathogenesis by direct 
actions on immature astrocytes and oligodendrocytes which express µ-opioid or κ-opioid 
receptors [86]. 
In other virus-induced demyelination, there is clear evidence that mouse hepatitis 
virus can directly infect and activate microglia during acute inflammation which 
eventually causes phagocytosis of myelin sheath and thus leading to demyelination 
during chronic inflammation stage [87]. Similar theory has been well established in 
multiple sclerosis, which is the most prevalent demyelinating disease, that immune-
activated microglia strip the myelin. Recent evidences show that microglia appear to be 
more phagocytotic in response to HIV-1 Tat and result in neuronal loss [88, 89]. 
Although there is no direct evidence indicating microglia phagocytosis of oligodendrocyte 
in neuroHIV [54], it is likely that the infected and activated microglia can also phagocyte 
oligodendrocytes and myelin sheath, leading to the myelin damage and consequent 
HAND pathogenesis.  
7. Myelin maintenance and remyelination in HIV-1-infected brain 
Repair of the damaged myelin sheath, which is called remyelination, is 
physiologically required to maintain the myelin homeostasis. The myelin injury in 
neuroHIV may also be induced by abnormalities of remyelination, in addition to loss of 
existing myelin sheath. Remyelination requires proliferation and survival of OPCs, 
migration of OPCs to the local lesion site, development from immature oligodendrocytes 
to myelinating mature oligodendrocytes. The alterations of OPC regulating signals 
related to remyelination process are found in HIV-1.  
7.1. Altered OPC proliferation and differentiation in HIV-1-infected brain 
13 
 
In HIV-1-infected brain, mild myelin damage is associated with an increase in 
oligodendrocyte number, but the number decrease in severe myelin damage [90]. In an 
agreement with the aforementioned results, mRNA levels of transcription factor Olig2, a 
marker expressed with higher levels in OPC and lower levels in mature oligodendrocytes 
[91], are elevated in the front cortex of patient with HIVE [48], indicating an increase of 
OPC proliferation is needed for repairing damaged myelin sheath. Mature 
oligodendrocytes defect is also observed in animal model of secondary degeneration, 
which represents additional loss of neurons, myelin, and glial cells through toxic events. 
Early onset of secondary degeneration triggers OPC proliferation, but the cell numbers 
decrease in a long-term [31]. However, Tat exposure reduces the population of 
undifferentiated Sox2+ NPC (ancestor of OPC) and Olig2+ OPCs, but progenitor survival 
is unaffected [85], suggesting the proliferation was interrupted. Tat may inhibit NPC 
proliferation by down-regulating cyclin D1, which is an important cell cycle component 
interacts with cyclin dependent kinase 4 and 6 [92] (Fig. 1C). Over all, HIV-1 infection or 
viral protein exposure tends to incline NPC fate toward generation of astroglia cells at 
the expense of neurons and/or oligodendrocytes [85, 93, 94]. Thus we consider OPC 
differentiation and maturation are likely to be the key point for remyelination in neuroHIV.  
7.2. Imbalance of OPC differentiation and remyelination in HIV-1-infected brain 
It has been shown that differentiation of OPCs into post-mitotic oligodendrocytes is a 
major check-point in the myelination process. As mentioned in Section 2, 
oligodendrocyte differentiation is controlled by various factors, which are most negative 
mediators. While molecular mechanisms in the regulation of developmental myelination 
are discussed in excellent review papers published elsewhere [95, 96], the direct 
interaction between HIV-1 and these molecules remains largely unknown. It is, however, 
believed that HIV-1 may disturb the complex regulating network leading to the 
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remyelination imbalance based on the following findings: 1) HIV-1 alters cell cycle by 
Wnt signaling pathways and further impact the cell proliferation and differentiation in 
different cell types, including peripheral blood mononuclear cells [97], HEK293 cells [98], 
and astrocytes [99]. 2) HIV-1 infection of primary-derived astrocytes altered astrocyte 
Wnt profile by elevating Wnt family members 2b and 10b [99]. 3) Elevation of secreted 
Wnt signal from astrocytes may negatively regulate oligodendrocyte differentiation in 
neuroHIV (Fig. 1C). 4) Notch-1 signaling is permissive for OPC expansion but inhibit 
differentiation and myelin formation [100]. 5) In Kaposi`s sarcoma cells, which is a 
neoplasm in HIV-1-infected individuals, overexpression of activated Notch-1 signaling is 
detected [101]. However, to our knowledge, there is no yet report on how 
OPC/oligodendrocyte Notch-1 signaling in responding to HIV-1. Moreover, 
overexpression of CD44, a predominant hyaluronan receptor widely expressed in 
nervous system, on precursor cells inhibits differentiation toward oligodendrocytes and 
promotes differentiation into astrocytes, thus plays a negative role in OPC differentiation 
and myelination [102, 103]. In lymphocyte cell lines of Jurkat and U937 cells, HIV-1 
infection-caused particle production is accompanied by CD44 up-regulation [104]. In 
HIV-1-related diffuse large B-cell lymphoma patients, the CD44 levels significantly 
increased compared with HIV-1-unrelated diffuse large B-cell lymphoma patients (87% 
vs. 56%) [105]. These findings suggest CD44 may play a role in HIV-1-related 
remyelination failure. 
Neurotrophins are important factors in the regulation of oligodendrocyte myelination 
and remyelination. The main cellular sources for neurotrophins in brain are astrocytes, 
microglial cells, and neurons, in addition to contribution of lymphocytes through the 
blood circulation. Being aware of excellent reviews on the alteration of neurotrophins in 
HAND [106] and immunological communications between oligodendrocytes and 
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microglia [107], we here focus on the HIV-1-induced alterations of neurotrophins that 
potentially associate with oligodendrocyte abnormalities. 
The platelet-derived growth factor (PDGF) is the most predominant mitogen for 
oligodendrocyte lineage cells. PDGF A and B chain both promote proliferation through 
activating PDGF receptor alpha (PDGFRα) expressed on OPCs, whereas the PDGF B 
chain appears to be more important for early NPC expansion [108, 109]. It has been 
shown that PDGF regulates OPC development via glycogen synthase kinase-3β (GSK-
3β) signaling pathway, which is a negative regulator of OPC differentiation and 
remyelination [110, 111]. PDGF-BB prevents NPC from Tat-mediated proliferating 
impairment by inactivating GSK-3β/β-catenin pathways and, this effect is significantly 
inhibited by the p38 and JNK inhibitors [112]. The levels of fibroblast growth factor (FGF), 
which is an important pro-survival signal to stimulate OPC proliferation [113], increased 
in the sera of HIV-1-infected patients [114, 115], but decreased in CSF [115]. FGF 
signaling complex is interrupted in HIV-1-infected brain, results in the abnormal 
activation of downstream signals including GSK-3β [116, 117], p38, ERK, and JNK 
cascades [118] in neurons through the surface receptors such as NMDA receptor and 
CXCR4, which are also expressed on oligodendrocytes [59, 119, 120]. In addition, HIV-1 
Tat and FGF-2 share a common core mechanism of unconventional secretion [121], 
although it is not clear whether they compete for the secretory routine. The brain-derived 
neurotrophic factor (BDNF), predominantly derived from astrocytes, has also been found 
to be essential for oligodendrocyte lineage development [122-125]. In rat primary 
neurons, gp120 promotes a time-dependent proBDNF accumulation at both intracellular 
and extracellular spaces by decreasing the expression level of intracellular furin, an 
enzyme required for cleavage and release mature BDNF,  leading to a reduction in 
mature BDNF (Fig. 1C). A similar imbalance in the ratio of proBDNF/mature BDNF was 
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confirmed in postmortem brains of HAND patients [126]. These findings suggest that 
HIV-1 decreases the brain BDNF level by infecting astrocytes and gp120-associated 
neurotoxicity, resulting in down-regulated remyelination. As BDNF is believed to protect 
neurons from HIV-1-induced apoptosis, thus the reduction of BDNF may also make the 
oligodendrocyte losing the support from neuronal axons that consequently cause myelin 
damage through “inside-out” mechanism as proposed [65]. 
Besides these signaling molecules, HIV-1 Tat interacting protein (TIP30), a co-factor 
that specifically enhances HIV-1 Tat-activated transcription [127], negatively regulates 
oligodendrocyte development. Overexpression of TIP30 dramatically inhibits the OPC 
differentiating progression, while knockdown of TIP30 enhances the differentiation of 
OPC remarkably [128]. Blockade of TIP30 may have dual benefits on inhibiting Tat-
dependent genes transcription and promoting OPC differentiation, which is a potential 
therapeutic strategy on HIV-associated demyelination. Ion channels are also involved in 
regulation of OPC development. Kv1.3 [129, 130], Kv1.6 [129], inward rectified K+ 
channel 4.1 [131, 132] play crucial roles in regulation of OPC/oligodendrocyte 
proliferation and differentiation. Generally, channels expressions on oligodendrocyte 
lineage cells correlate with differentiating stages and the correlations are more complex 
in OPCs than in oligodendrocytes. Particularly, Kv1.3 channel plays a crucial role in 
G1/S transition in proliferating OPCs through regulating AKT signaling [130, 133]. 
Moreover, L-type voltage-operated Ca2+ channel 1.2 knockdown induces a decrease in 
the proportion of oligodendrocytes expressing myelin proteins, and an increase in the 
population of immature oligodendrocyte [134]. 
Very recent study proposed that myelin injury in HAND is partially due to effects of 
antiretroviral drugs on oligodendrocyte survival and differentiation. The common 
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prescribed antiretroviral drugs, ritonavir and lopinavir, impair both the differentiation of 
OPCs into myelin-producing oligodendrocytes and the maintenance of myelin proteins in 
vivo. Ritonavir induces accumulation of reactive oxygen species, which arrest 
oligodendrocyte differentiation process [135, 136]. Controversial results were reported in 
HIV-1-infected children in Africa that significant myelin loss in cART-naïve children was 
observed in comparison with cART-treated children. However, cART-treated children 
also exhibited a significant myelin loss in the corpus callosum [137]. Interestingly, 
myelin-related genes encoding myelin-associated oligodendrocyte basic protein, myelin 
transcription factor 1 and myelin basic protein are down-regulated in both cART-treated 
and untreated HAND patients [138]. Apparently, the impact of antiretroviral drugs on 





Figure 1. Potential mechanisms for HIV-induced oligodendrocyte/myelin injury. 
A, HIV-1 Tat enhances JCV transcription and replication. B, HIV-1 proteins induce 
oligodendrocyte apoptosis. C, The progenitor cell proliferation and differentiation are 
interrupted in neuroHIV. 
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8. K+ channels in brain: implications for channelopathy in HAND  
K+ channels are highly diverse and expressed on almost all cell types. Normal 
function of K+ channels is required for basic cell survival and normal activity. In contrast, 
K+ channel hyperactivation, especially outward K+ currents conducted by KV channels, 
may cause cell apoptosis in a variety of cell types via apoptotic volume shrinkage. 
Enhanced K+ efflux can resultant in apoptotic cell shrinkage, downstream caspase 
activation, and further DNA fragmentation [84, 139]. Hyperactivation of K+ channel can 
also cause immune cells activation like macrophages, microglia, and T lymphocytes [140, 
141]. The non-specific KV blocker 4-AP has been approved by the Food and Drug 
Administration to proceed to clinical trial for neurodegenerative disease [142]. Previous 
studies from our laboratory describe apoptosis of rat cortical neurons associated with 
enhancements of K+ efflux conducted by voltage-gated K+ (KV) channels in HAND. KV1.3 
and KV1.5 in microglia are highly involved in pathogenesis of experimental autoimmune 
encephalomyelitis animal models and HAND [143-145]. Microglia KV1.3 is involved in 
microglial activation-induced neuronal injury [141]. These data suggest KV channels are 
closely associated with HIV pathogenesis.  
8.1. K+ channels in neurons 
Action potential propagation is the most essential character for neural function. The 
two most important properties of axonal action potentials are high conduction velocity 
with quick recovery. High velocity requires rapid inactivation of Na+ channels and a high 
K+ permeability [146]. It is believed that Na+ channels are enriched in the node of 
Ranvier, meanwhile, KV channels are enriched at the juxtaparanodes (JXP) (Fig. 2). The 
cluster of KV1 family members on neuronal axon JXP indicates myelination [147] [148]. 
In coculture model of hippocampal neurons and oligodendrocytes, endogenous KV1.2 
channels enriched in JXP of myelinated hippocampal axons after two weeks of 
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coculturing neurons and oligodendrocytes [149]. In contrast, KV1.2 distribution on 
myelinated axons is disrupted within demyelinated lesions in the WM of spinal cord in 
experimental autoimmune encephalomyelitis [150]. These data suggest that KV channels, 
particularly KV1.2, are essential for axon cable properties. 
It has been reported that depolarization-activated K+ currents limit the peak 
amplitude of the depolarizing after-potential in both lizard and rat axons [151]. However, 
overexcited KV channels hyperpolarize the neuronal membrane increasing the threshold 
to trigger action potential, even leading to neuronal death. As mentioned above, 
research on programmed cell death has demonstrated the necessary contribution of K+ 
channels in the process of apoptosis. In previous experiments, our laboratory confirmed 
the association of rat cortical neuron apoptosis and increased K+ channel currents in 
HIV-1 proteins treated cells [143-145]. While several KV channel subtypes have been 
implicated in cortical neuron apoptosis, including KV2.1 [152], KV1.1 [144], KV3.4 [153], 
KV4.2, and KV4.4 [154], the specific subtypes involved in HAND pathology and the 
mechanism underlying its dysfunction remains to be extensively characterized. 
Collectively, these observations suggest that specific KV channel subunits may perform 




Figure 2. The distribution of voltage-gated ion channels on neural axon. KV1 
family members KV1.2 express at the JXP region of axon. Voltage-gated Na
+ channels 




8.2. K+ channels in oligodendrocytes 
As early in 1988, Betty et al. performed whole cell clamp patch on cultured ovine 
oligodendrocytes. They found oligodendrocytes express outward currents considered as 
K+ currents, because that represent an transient-inactivating component and non-
inactivating component, which showed reversal potential at -66 mV and were sensitive to 
KV blockers [155]. The transient component decreased within the oligodendrocyte 
lineage cell development, while accompanied by an up-regulation of steady-state 
outward and inward rectifier current [129, 155, 156]. Generally, KV channel expression 
on oligodendrocyte lineage cells correlate with differentiation stage and are more 
complex in OPCs than in oligodendrocytes. To date, KV1 subfamily is relatively well 
studied in oligodendrocytes [129, 130, 157]. In addition to what has been addressed in 
section 7.2., in cultured oligodendrocytes from basal forebrain, high concentration of KCl 
(25 mM), which can depolarize cell membrane via inhibiting K+ efflux, approximately 
doubles BDNF mRNA expression, while nerve growth factor (NGF) and neurotrophin-3 
(NT-3) expression is not altered. The number of cells expressing mature myelin basic 
protein positive (MBP+), which is a structural protein of myelin sheath, increased [158]. 
These data suggest that KV channels activity affect the trophic function of 
oligodendrocytes that further affect neuronal function and survival. 
Since oligodendrocytes are the most important cell type for myelin sheath production 
and maintenance in CNS, K+ channels may act as a mediator in myelin injury and 
remyelination by regulating OPC/oligodendrocyte biogenesis. It is not surprising that 
apoptosis of oligodendrocytes is an important component of lesion formation. The crucial 
role of oligodendrocyte indicates any damage or/and loss of oligodendrocytes may relate 
to the observed myelin damage and cognitive deficits in HAND patients. 
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8.3. K+ channels in astrocytes 
Astrocytes are indispensable for neuronal survival and function, including an 
additional beneficial effect on oligodendrocyte regeneration during remyelination. 
Astrocytes pivotally regulate extracellular concentration of glutamate and K+ to support 
neuron function [159]. During normal neuron firing, K+ ions flow to the extracellular space 
from neurons. Increased extracellular K+ concentration can potentially cause membrane 
depolarization. Kir4.1 channels in astrocytes may play a critical role in K+ buffering to 
avoid neuronal membrane depolarization, which may result in interruption of axonal 
conduction and synaptic transmission [160, 161] [162-164]. So far, there is no clear 
evidence indicates close association of astrocyte K+ channels and HAND pathogenesis. 
Astrocyte Kir channels may serve to provide the network of regulation in K+ and 
glutamate concentration in brain [161].  
8.4. K+ channels in microglia 
Microglia are the residual immune cells in the brain [165]. The protective effect of 
microglial immune activation in HAND is mostly temporary. Hyperactivation of microglia 
and macrophages are often accompanied with disease progression.  In addition, 
depletion of these cells significantly decrease the severity of HIV-1-related CNS 
neuropathology [166]. 
Microglia express several K+ channel families including KV1, KV3, Kir [167-169]. Kir 
channels are often considered to be functional on resting microglia. KV1.3 and KV1.5 are 
highly involved in pathogenesis of HAND [140, 141, 170]. Activation of microglia leads to 
neuronal injury through a mechanism requiring microglial KV1.3 activity. Data published 
from our lab found that collected culture medium from KV blocker-treated microglia 
attenuate HIV-1 Tat-induced neuronal apoptosis that corresponds with Erk1/2 MAPK 
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kinase activation. Moreover, enhancement of outward K+ currents on microglia increases 
the cell motility [141]. Blockade of KV1.3 significantly reduce microglia migration to 
cellular debris [171]. In addition, Ca2+ activated K+ channels 3.1 (KCa3.1) promote rat 
microglia migration [172]. KCa3.1 blocker reduced the microglial activities of 
phagocytosis and chemotactic in primary culture [173]. 
Summary and Discussion 
There are increasing interests in myelin sheath loss and WM damage in HIV-1 brain. 
The clinical and postmortem manifestations of myelin damage of HAND patients, 
contributions of BBB integrity disruption, oligodendrocyte apoptotic molecular 
mechanisms, and OPC regulation imbalance in oligodendrocyte/myelin abnormalities 
have been addressed in this chapter. All of these factors potentially involve in generation 
of HAND pathology. Given that milder forms of HAND remain prevalent and HIV-1 
proteins and toxic factors released from infected cells persist in brain even in the era of 
cART, the studies on direct toxicity of HIV-1 viral proteins on oligodendrocytes and 
OPCs, as well as neurons, are emerging. Because the transcription of HIV-1 viral protein 
continues in the CNS even the viral detection is minimal [174], this concept orchestrates 
with the context of changed HAND pathogenesis in cART era, of which inflammation, 
encephalitis, and neurodegeneration has been significantly decreased by the advent of 
cART. The ways on the regulation of oligodendrocyte lineage cell development are well-
established including the extracellular pathways, cell to cell contact, and intracellular 
pathways. Since NG2+ cell is the biggest population of progenitor cells in human adult 
brain, the decreased absolute cell number and proliferation of NPC and OPC may be 
less contributive to myelin deficits in HAND. However, the evidences of HIV-1-related 
OPC differentiation and remyelination imbalance serve to better understand the impact 
25 
 










Human immunodeficiency virus protein Tat 
induces oligodendrocyte injury by enhancing 
outward K
+




Brain white matter damage is frequently detected in patients infected with human 
immunodeficiency virus type 1 (HIV-1). White matter is composed of neuronal axons 
sheathed by oligodendrocytes, the myelin-forming cells in central nervous system. 
Oligodendrocytes are susceptible to HIV-1 viral trans-activator of transcription (Tat) and 
injury of oligodendrocytes results in myelin sheath damage.  It has been demonstrated 
that activation of voltage-gated K+ (KV) channels induces cell apoptosis and 
oligodendrocytes predominantly express K+ channel KV1.3.  It is our hypothesis that Tat 
injures oligodendrocytes via activation of KV1.3.  To test this hypothesis, we studied the 
involvement of KV1.3 in Tat-induced oligodendrocyte/myelin injury both in vitro and ex 
vivo.  Application of Tat to primary rat oligodendrocyte cultures enhanced whole-cell 
KV1.3 current recorded under voltage clamp configuration and confirmed by specific 
KV1.3 antagonists Margatoxin (MgTx) and 5-(4-phenoxybutoxy) psoralen (PAP).  The 
Tat enhancement of KV1.3 current was associated with Tat-induced oligodendrocyte 
apoptosis, which was blocked by MgTx and PAP or by siRNA knockdown of KV1.3 gene.  
The Tat-induced oligodendrocyte injury was validated in cultured rat brain slices, 
particularly in corpus callosum and striatum, that incubation of the slices with Tat 
resulted in myelin damage and reduction of myelin basic protein which were also 
blocked by aforementioned KV1.3 antagonists.  Further studies revealed that Tat 
interacts with KV1.3 as determined by protein pull-down of recombinant GST-Tat with 
KV1.3 expressed in rat brains and HEK293 cells. Such protein-protein interaction may 
alter channel protein phosphorylation, resultant channel activity and consequent 
oligodendrocyte/myelin injury. Taken together, these results demonstrate an involvement 
of KV1.3 in Tat- induced oligodendrocyte/myelin injury, a potential mechanism for the 
pathogenesis of HIV-1-associated white matter damage. 
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Neurologic complications of human immunodeficiency virus type 1 (HIV-1) infection 
remain common in the era of effective combination antiretroviral therapy (cART).  Up to 
half of infected individuals develop HIV-1-associated neurocognitive disorders (HAND), 
the cause(s) remain obscure. Many studies have revealed a preferential damage to 
cerebral white matter in HIV-1-infected brain [8, 41, 82, 91], and such damage is 
prevalent even in the era of cART and more severe in patients with HAND [111, 127]. 
Structure magnetic resonance imaging and  diffusion tensor imaging studies in HIV-1-
infected individuals have revealed a subcortical white matter damage mainly in the 
regions of the corpus callosum, internal capsule and other brain regions [41, 54, 91, 92, 
111, 176].  Moreover, cognitive impairment in HIV-1-infected individuals with AIDS was 
found to be associated with white matter injury in the corpus callosum, internal capsule, 
and superior longitudinal fasciculus [41, 176]. It appears that subcortical damage in 
white matter plays a more important role than cortical damage in the mediation of HAND 
symptoms which are predominantly of the subcortical type [22, 24, 177, 178].  
Cerebral white matter consists mostly of myelinated axons and axonal myelination is 
formed by oligodendrocytes. The integrity of the myelin sheaths is essential for the 
propagation of nerve impulses along axons. It has been demonstrated that myelin pallor, 
an abnormality that could reflect a decrease in myelin components [29, 179], is 
frequently seen in patients with HIV-1 encephalitis and in cART naïve subjects. Myelin 
sheath damage and changes in numbers of oligodendrocytes have also been observed 
in HIV-1-infected individuals [90, 180]. In vitro studies have shown that exposure to 
recombinant viral envelope protein gp120 resulted in alterations of oligodendrocyte 
functional activity and myelin formation in rat oligodendrocytes maintained in a cell 
culture system [14, 15], exampling HIV-1 protein impairment of oligodendrocyte/myelin, 
which may lead to axonal injury, demyelination and ultimately white matter damage. 
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Nevertheless, how HIV-1 proteins induce oligodendrocyte/myelin injury is not fully 
understood. 
Increasing evidence indicates that activation of voltage-gated K+ channels (KV) is an 
essential pathway in programmed cell death [26, 84] and enhancement of outward K+ 
current results in neural cell apoptosis [181, 182]. Oligodendrocytes express several 
subtypes of KV channels including a predominant KV1.3 [129, 183]. A decrease of KV1.3 
expression or outward K+ current in oligodendrocytes is essential for synthesis of myelin 
structural proteins and suppression of outward K+ current promotes oligodendrocyte 
maturation and survival. These results suggest a role of KV1.3 in the regulation of 
oligodendrocyte functionality [130, 133].  Moreover, activation of p53 has been detected 
in the oligodendrocyte lineage cells in the postmortem brains of HAND patients, but not 
in control brains [83], suggesting oligodendrocytes undergo apoptosis in HIV-1-infected 
brains. Thus, it is our hypothesis that continued viral replication and viral proteins induce 
oligodendrocyte/myelin injury by activation of oligodendrocyte KV1.3 channels, leading to 
myelin/white matter damage and HAND pathogenesis. To test this hypothesis, we 
studied how HIV-1 protein Tat induces oligodendrocyte/myelin injury, as infected brain 
cells continuously express and release Tat protein despite the controlled viral replication 
[184, 185]. Our results showed that HIV-1 Tat enhances outward K+ current conducted 




2. Materials and Methods 
2.1. Materials. HIV-1 Tat IIIB was purchased from Immunodiagnostic, Inc. 
(Woburn, MA). Tat was dissolved in sterile distilled water and, aliquots of Tat were kept 
as 50 µg/ml stock solution at -80 °C. 
2.2. Animals. Pregnant Sprague-Dawley rats were purchased from Charles River 
(Wilmington, MA) and maintained under the ethical guidelines for the care of laboratory 
animals, and all animal procedures were reviewed and approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University of Nebraska Medical Center.  
2.3. Oligodendrocyte preparation and culture. Oligodendrocyte cell cultures 
were prepared as described previously [186] and all culture materials were purchased 
from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Briefly, P1-2 neonatal rat 
pups were decapitated with large scissors and place the heads in 10 cm-petri dish filled 
with cold Hank`s buffered salt solution (HBSS). Microdissecting scissors was used to 
carefully cut skin and skull along the midline from neck toward the nose. Brains were 
taken out with a spatula and placed to another petri dish contained cold HBSS. The 
meninges were removed with forceps under a dissection microscope. Cortex tissue was 
dissociated by cutting the brain to two hemispheres and removing hippocampus and 
olfactory bulbs.  
Dissociated cortex tissue was incubated in 0.25% trypsin and 200 U DNase 
contained in HBSS at 37 °C for 15 min. Then 1 ml FBS was added to stop trypsinization. 
Homogenate was collected into a 50-ml tube and the contents were triturating by 
pipetting several times to separate any tissue block. The tissue suspension was next 
collected into a clean 50-ml tube and followed by centrifugation at 1500 r.p.m. for 10 min. 
The supernatant was removed and 20 ml HBSS was added to re-suspend the remained 
cells/tissues by triturating cells/tissue for about 20 times. The remaining tissue 
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suspension was passed through nylon mesh with pore diameter size of 100 µm and 40 
µm sequentially. Cells were collected by centrifugation at 1500 r.p.m. for 10 min. 
Collected cells were re-suspended in DMEM (with L-glutamine and sodium pyruvate, 
Cellgro, Manassas, VA) supplemented with 20% FBS (Gibco, Grand Island, NY) and 1% 
penicillin/streptomycin (Gibco). Mixed glia cultures were grown on poly-D-lysine-coated 
T75 flasks (Thermo, Nazareth, PA) for 10 d and refreshed medium every 3 d. 
To isolate OPCs, the flask was pre-shaken for 1 h on an orbital shaker at a speed of 
200 r.p.m. in order to remove microglia. OPCs were isolated by shaking overnight at 200 
r.p.m. at 37 °C. Cell suspensions were transferred into non-treated 10 cm petri dishes for 
30 min to further separate OPCs by differential adhesion (astrocytes and microglia can 
attach to bottom faster than OPCs/oligodendrocytes). OPC-contained supernatant was 
collected by slightly swirling petri dish and transferring the supernatant in a sterile 50-ml 
tube, then the supernatant was passed through 40 µm nylon cell strainers. OPCs were 
collected by centrifugation at 800 r.p.m. for 5 min and suspended in OPC medium 
(described below). OPCs were plated onto poly-D-lysine-coated coverslips, culture 
dishes, or plates in OPC culture media in a density of 1 × 104/cm2.  
Different stages of oligodendrocytes are characterized by unique combinations of 
genes [187], and three major markers were chosen to specify the following stages in the 
present study: NG2+ OPCs, galactocerebroside (GalC)+ immature oligodendrocytes, and 
MBP+ mature oligodendrocytes. Basal chemically defined medium (BDM) was made of 
DMEM containing 0.1% BSA, 1% Insulin-Transferrin-Selenium (Gibco), 10 nM D-biotin, 
and 10 nM hydrocortisone. NG2+ OPCs were maintained in BDM supplemented with 10 
ng/ml PDGF-AA (homodimer PDGF consists of 2 A domains) and 10 ng/ml bFGF (both 
from Peprotech, Rocky Hill, NJ) for 0-7 d. GalC+ immature oligodendrocytes were 
cultured in the same medium as NG2+ OPCs for additional 3 d. MBP+ mature 
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oligodendrocytes were obtained by transferring cells to differentiating medium (BDM, 15 
nM triiodothyronine, 10 ng/ml CNTF (Peprotech) and 5 µg/ml N-acetyl-L-cysteine) for 2-3 












Figure 3. Primary culture of oligodendrocyte lineage cells. Panel A, B, C, 
representative fields of OPC culture of 1, 4, and 7 d representatively after isolation from 
mixed glial culture. Panel D, a representative field of oligodendrocyte cultured in 
differentiating medium for 2 d. A, B, C, D images were taken under white field (×200). E, 
Portrayed cell purity revealed by staining with NG2, MBP and GalC respectively 
depends on different stages of cells. The nuclei were visualized by Dapi staining. All 
Images were visualized by fluorescent microscopy (×400). Cell counting is normalized by 





2.4. Electrophysiology. Cells were seeded onto 3.5-cm culture dishes for whole-cell 
recording of ionic currents. Recording electrodes were pulled from borosilicate glass 
micropipettes (WPI Inc., Sarasota, FL) with a P-97 horizontal micropipette puller (Sutter 
Instruments, Novato, CA) to a resistance of 5-8 MΩ. The electrode solution contained (in 
mM): 140 KCl, 2 CaCl2, 2 MgCl2, 11 EGTA, 10 HEPES/KOH, pH7.3, and had an 
osmolarity of 300 mOsm, as measured by a vapor pressure osmometor (WESCOR, 
Logan, UT). The standard bath solution contained (in mM): 140 NaCl, 5.4 KCl, 2 CaCl2, 
1 MgCl2, 10 HEPES/NaOH, pH7.3. D-sucrose was used to adjust the osmolarity of this 
solution to 305 mOsm prior to recording. Stock solutions of KV1.3 specific inhibitors, 5-
(4-phenoxybutoxy) psoralen (PAP, Sigma) and Margatoxin (MgTx, Sigma), were 
prepared in deionized water before being diluted to a working concentration with bath 
solution, and applied by super-fusion. External super-fusion of the cells was performed 
by exchanging the bath at a rate of 1 ml/min. A Burleigh micromanipulator (PC-5000, 
EXFO, Canada) was used to position the recording electrode.  
Under 40 × objective lens, cells appeared bright and dimensional were chosen to 
patch at. The electrode solution was filled into electrodes by a syringe linked with a 
micro-loader tip. Air bubbles were eliminated by tapping pipette several times. Then the 
glass electrode was placed onto the pipette holder connected with head stage. A 
positive pressure was provided to electrode by giving 0.2 ml air through syringe. 
Following this, the electrode was placed into the bath solution and off-set was adjusted 
to zero. The oscilloscope showed square current response to the seal test. Under 
voltage-clamp mode, the electrode resistant was checked in membrane test function in 
Clampex software.  
Under the 10 × objective lens, adjusted the focus onto the tip of electrode and then 
switched the objective lens to 40 ×. The electrode was slowly approached to the chosen 
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cell by the micromanipulator. During approaching, it was important to keep the focus on 
the tip of electrode but not the cells. When the cells were becoming clearer, the 
electrode tip was being closer to the cell. The electrode tip was positioned to touch the 
cell surface at the middle right where close to the center of cell body. Once get touched, 
the positive pressure was released and instead, a negative pressure was applied to gain 
a GΩ seal. The oscilloscope showed flat while GΩ seal was achieved. Followed seal, the 
fast capacitance was corrected. 
To rapture the cell membrane, further suction was applied by the syringe. Once the 
membrane was broken through, the current response showed exponential decay. The 
membrane capacitance of each cell was read and recorded under cell mode in 
membrane test function. The membrane capacitance was adjusted by at least 70%. The 
currents were recorded in Clampex.  
Whole-cell K+ currents were induced by applying voltage steps from -150 mV to +60 
mV in increments of 15 mV, and current amplitudes were measured at the peak for each 
test potential. Current density (pA/pF) was calculated by dividing the digitized current 
values by whole-cell capacitance, which represents cell membrane surface area. All 
experiments were done at room temperature (22-23 °C). Recordings were obtained with 
an Axopatch-200B amplifier (Molecular Devices, Sunnyvale, CA). Current signals were 
filtered at 1 kHz and digitized at 5 kHz using a Digidata 1440A interface (Molecular 
Devices). The current and voltage traces were displayed and recorded on a computer 
using Clampex 9.0 data acquisition and analysis software (Molecular Devices). Data 
were analyzed by Clampfit 10.0 (Molecular Devices). All final graphics in the present 
work were constructed by Origin 8.0 (OriginLab, Northampton, MA).  
2.5. MTT Assay. MTT assay was used to assess cell viability. Cells were cultured 
in 48-well plates for MTT assay to minimize diversity between replicates. The 3-(4,5-
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Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) was prepared in sterile 
PBS at concentration of 5 mg/ml (10 ×) and stored at -20 °C. The working solution was 
made by diluting the stock MTT solution 10 times with DMEM. The pre-treated cells 
were exposed to working solution and incubated in 37 °C for 2 h. The MTT solution was 
discarded and replaced with 150 µl dimethyl sphingosine (DMSO). Cells were then 
shaken for 15 min at 200 r.p.m. for completed lysis. The dissolved solution was 
transferred of 100 µl from each well to a 96-well plate and, 96-well plate was eventually 
placed to a plate reader and tested the optical density at 560 nm.  
2.6. Apoptosis Assay.  
A) Terminal deoxynucleotidyl transferase dUTP nick end labeling (Tunel) staining 
was performed with the in situ cell death detection kit (Fluorescein, Roche Applied 
Science, Indianapolis, IN). Cultures plated on coverslips were fixed in 4% 
paraformaldehyde for 1 h at room temperature and permeabilized with 0.1% Triton X-
100 for 30 min. Cover slips were washed 5 min × 3 times with PBS. Tunel reaction 
mixture was made by adding label solution to enzyme solution (terminal 
deoxynucleotidyl transferase and fluorescein-labeled nucleotides) at a ratio of 1:50. 
Each cover slip was prepared 30 µl of reaction mixture. The reaction mixture was 
applied onto clean Para film and, cover slips were flipped onto reaction mixture solution 
drops and incubated for 90 min at 37 °C. After washing, coverslips were mounted in 
vectashield mounting medium with Dapi stain (Vector Laboratories, Burlingame, CA) and 
cells were visualized by a fluorescent microscope. Apoptosis was assessed in each of 
three experimental preparations by examining 10 microscopic fields per experimental 
group.  
B) Propidium iodide (PI) staining. Fixation of cultures was performed same as 
mentioned above in Tunel staining. Cells were briefly equilibrated in 2 × SSC (0.3 M 
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NaCl, 0.03 M sodium citrate, pH 7.0), and then incubated the in 100 μg/ml DNase-free 
RNase in 2 × SSC for 20 minutes at 37°C to remove RNase. Coverslips were rinsed 1 
minute × 3 times with 2 × SSC. PI solution was made at a concentration of 500 nM by 
diluting the 1 mg/ml (1.5 mM) stock solution 1:5000 in 2 × SSC. Cells were incubated 
with the diluted working staining solution for 1 m. Cells were washed 4 times with 
shaking in 2 × SSC. Excessed buffer was drained from the coverslips and, coverslips 
were mounted in vectashield mounting medium with Dapi stain. The analysis procedures 
were performed same as Tunel assay. 
2.7. Brain slices culture. Coronal brain slices were prepared from 21-d-old 
neonatal Sprague-Dawley rats. The culture procedures were performed as described by 
Stoppini, etc [188]. All surgical instruments were autoclaved. Vibrotome (Campden 
instruments, MA752 Motorised advance vibroslice) was sterilized by exposure to 
ultraviolet light for 1 h. The 2% of agarose gel was prepared in sterilized water to help 
positioning rat brains. Artificial cerebrospinal fluid (ACSF) contained (in mM) NaCl 124.0, 
KCl 3.0, CaCl2 2.0, MgCl2 2.0, NaH2PO4 1.25, NaHCO3 26.0, and glucose 10.0, pH 7.2. 
The culture medium consisted of 50% MEM with HEPES (Gibco), 25% horse serum 
(Atlanta biological, Flowery Branch, GA),  25% Hank`s solution (Invitrogen), and 6.5 
mg/ml glucose. Inserts with 30 mm diameter, sterile, porous (0.8 µm), transparent and 
low-protein-binding membrane were placed into 6-well plates as scaffold for the brain 
slices.  
Agarose gel was cut to a small cube and fixed onto stage of vibrotome by super glue 
(Fig. 4 Top). Rats were anesthetized with isoflurane, and then quickly decapitated by 
small animal decapitator (Stoelting, 51330). The whole brain was dissected and fixed 
onto the stage of vibrotome next to agarose gel cube (Fig. 4 Top). The stage was placed 
into cutting chamber filled with pre-cooled and oxygenated ACSF. Oxygen was provided 
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to ACSF during the whole cutting procedure. Slices of 400 µm were cut and separated in 
ACSF. The slices were then transferred on to culture insert plated in 6-well plate with 1 
ml/well pre-warmed (37 °C) culture medium. The 6-well plates were then kept in 
incubator at 37 °C with 5% CO2.  It was important to keep the slices placed on the 





Figure 4. Illustration of the cutting and culturing technique. Top: photograph of 
cutting brain slices. Bottom: photograph of a culture plate containing brain slices. 




2.8. Cryostat section.  The brain slices were washed with PBS for 3 times after 
treatments, then fixed with 4% paraformaldehyde for 24 h. The tissue was then 
progressively changed into graded 10%, 20%, and 30% sucrose/PBS solution each for 
24 h for cryoprotection. The tissues were orientated and embedded within OCT and 
quickly frozen in -80 °C. The tissue blocks were cut into 10 µm sections by Leica 
cryostat (LEICA CM1850 UV).  
2.9. Immunofluorescences. The prepared brain sections were blocked and 
permeabilized in 10% goat serum/0.1 % Triton/PBS solution for 30 min in room 
temperature. The slides were dried carefully, and the tissue sections were circled by 
hydrophobic pen, followed by applying 50 µl of the primary anti-rat MBP antibody (1:200, 
Chemicon) for each section. Slides were placed in a humidified chamber and incubated 
at 4 °C overnight. Next day, after washing the sections with PBS 5 min × 3 times, 
sections were incubated in goat anti-rat fluorescent secondary antibody (1:1000, 
Invitrogen) for 2 h in room temperature by using the same technique as described for 
primary antibody incubation. Sections were washed 5 min × 3 times and mounted with 
coverslips in vectashield mounting medium with Dapi (Vector Laboratories, Inc. 
Burlingame). The myelin sheath was visualized under fluorescent microscope.  
2.10. Total protein extraction. The whole cell lysates were prepared in RIPA 
buffer (BioRad, Hercules, CA) while tissue was lysed in tissue extraction reagent 
(Invitrogen). In details, following experimental treatments, cells or brain tissue were 
washed twice with ice-cold PBS and then PBS was aspirated. For cultured cells, 150 µl 
RIPA buffer supplemented with protease inhibitor was added to each well of 6-well plate. 
Cells were detached by scraping the well bottom and gently transferred into a 
microcentrifuge tube. For brain tissue, dissected corpus callosum and striatum from 
cultured brain slices were put into separate tubes, followed by addition of 200 µl tissue 
homogenate reagent to each tube. Sonication was performed 3 times for 15 seconds to 
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lyse brain tissues. Homogenate was then projected to a freeze-thaw cycle for complete 
lysis. Cell lysate or tissue homogenate were centrifuged at 10,000 r.p.m. for 10 min and 
supernatant was collected to a fresh tube. Next, 20 µl of each sample was taken out for 
protein concentration determination. A quarter of the sample volume of 5 × loading 
buffer was added to protein samples. Protein samples were denatured by boiling water 
for 7 min, and stored in -20 °C for western blotting. 
5 × loading buffer consisted of 0.25% Bromophenol blue, 0.5 M  dithiothreitol, 50% 
glycerol, 10% sodium dodecyl sulfate, and 0.25 M Tris-Cl (pH 6.8). 
2.11. Extraction of total membrane proteins. Membrane protein enriched 
fraction was extracted by Membrane Protein Extraction Kit (BioVision Inc, CA). Cells 
were cultured in 6-cm culture dishes for membrane protein extraction. After experimental 
treatments, cells were washed twice with ice-cold PBS. Firstly, 1 ml homogenization 
buffer was applied to each culture dish. Cells were scraped and then homogenized by 
vortex for about 10 times. Homogenate was then collected to a 1.5-ml tube and, 
centrifuged at 700 g for 10 min at 4 °C. The supernatant was transferred to a fresh tube 
and the pallet was discarded. Collected supernatant was centrifuged from at 10,000 g for 
30 min at 4 °C. 
Following the centrifugation, protein would be separated to the cytosol protein 
fraction (supernatant) and the total cellular membrane protein fraction (pallet). Dissolve 
the pellet in 60 µl 0.5% Triton X-100 in PBS buffer. Then 20 µl from each sample was 
taken for concentration determination. 
2.12. Protein concentration determination.  The BCA protein assay kit 
(ThermoFisher Scientific, Waltham, MA) was employed to quantify protein concentration. 
BCA working reagent was prepared by mixing 50 parts of BCA Reagent A with 1 part of 
BCA reagent B. The needed total volume of working reagent was determined by the 
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following equation: (number of standards + number of unknowns) × (number of 
replicates) × 100 µl = total volume of working reagent required. 
Standards were prepared by diluting 2 mg/ml albumin ampules in working reagent to 
200, 100, 50, 25, 12.5 µg/ml. Then 100 µl of each standard was put into a 96-well plate. 
At separate wells, 100 µl of working reagent only was placed as zero. Next, 10 µl of 
each unknown samples was diluted to 90 µl working reagent. Every standard and 
sample was duplicated. After all samples were prepared, the plate was incubated in 
37 °C for 30 min. The plate was then placed in a plate reader and the absorbance of all 
the samples were measured with the testing wavelength at 560 nm. 
 Standard curve was made by plotting the average blank-corrected measurement for 
each albumin standard versus its concentration in µg/ml. The standard curve was used 
to determine the protein concentration of each unknown sample. The volume for 15 µg 
protein of each sample was calculated and then the denatured samples were projected 
to Western blotting. 
2.13. Western blotting. 10 × Tris/glycine buffer, 10 × Tris/glycine/SDS buffer, 10% 
SDS, and 30% Acrylamide/bis solution were all purchased from Bio-Rad. The 10 × TBS 
(Tris-buffered saline, 1 liter) was prepared by dissolving 24.2 g Tris base, 80 g NaCl in 
distilled water, and adjust pH to 7.6 with HCl. Washing buffer was prepared by diluting 1 
ml 100% Tween-20 to 1 liter 1× TBS (TBST). Separating gel (10% )consisted of 1.5 mM 
Tris-HCl (pH 8.8) 2.5 ml, ddH2O 4.0 ml, 30% acrylamide/bis solution 3.3 ml, 10% SDS 
100 μl, 10% ammonium persulfate 100 μl, and TEMED 5 μl. Stacking gel (5%) consisted 
of 1mM Tris-HCl (pH 6.8) 0.63 ml, ddH2O 3.4 ml, 30% acrylamide/bis solution 0.83ml，
10% SDS 100 μl，10% ammonium persulfate 100 μl，TEMED 5 μl. 
45 
 
 Proteins were firstly separated by electrophoresis depending on the molecular weight. 
In details, 15 µg protein of each sample was loaded onto SDS-polyacrylamide gels. 
Electrophoresis was run under 70 mV constant voltage and switched to 110 mV when 
samples enter lower separating gel. Electrophoresis was stopped when the 
Bromophenol blue reached the bottom edge of SDS-polyacrylamide gel. 
 After electrophoresis, proteins were transferred from gel to a polyvinylidene difuoride 
(PVDF) membrane by 100 mV constant voltage in 1 × Tris/glycine/SDS buffer containing 
20% methanol for 70 min at 4 °C. The PVDF membrane was then blocked in 5% dry milk 
(3% BSA for phosphorylated-protein examination) in TBS for 1 h in room temperature. 
Following blocking, membranes were incubated in primary antibodies diluted in blocking 
buffer at 4 °C overnight. Primary antibodies were rabbit polyclonal anti-KV1.3 (1:100, 
Alomone Lab, Israel), rat monoclonal anti-MBP (1:500, MAB386, Chemicon/Millipore, 
Billerica, MA) and mouse monoclonal anti-β-actin (1:5000, Sigma). Afterwards, 
membranes were washed in TBST 10 min × 3 times and then incubated in HRP-
conjugated anti-rabbit, anti-rat or anti-mouse secondary antibodies (1:10,000, all from 
Jackson ImmunoResearch Laboratories, West Grove, PA) for 1.5 h at room temperature. 
Finally, membranes were washed in TBST 10 min × 3 times and incubated with Pierce 
ECL Western blotting substrate (Thermo Scientific, Rockford, IL), imaged by the 
FluorChem M system (ProteinSimple, Santa Clara, CA), and band densities were 
measured by Alphaview software (ProteinSimple). 
2.14. siRNA silencing. Pre-designed ON-target plus SMARTpool siRNA against 
rat KCNA3 (KV1.3, NM-019270) mRNA was purchased from Dharmacon, Inc. (Chicago, 
IL). Non-targeting (NT) siRNA (rat) (Dharmacon, Inc) was transfected at the same 
concentration as control. KV1.3-siRNA and NT-siRNA were transfected 72 h in prior to 
gaining the protein level knockdown. 
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OPCs were plated into 6-well plates at a density of 0.35 × 106 cells/well. Stock siRNA 
was diluted to 5 μM siRNA solution in RNase-free siRNA buffer solution from stock 
solution in a sterile tube. For each well, 10 μl of the prepared siRNA was diluted to 190 
μl DMEM, labeled as Tube A. In separate tubes, 2 μl DharmaFECT transfection reagent 
was diluted with 198 μl DMEM labeled as Tube B. Each tube was shaken to mix solution 
and incubated at room temperature for 5 min. The content was gently mixed from Tube 
A to Tube B by pipetting carefully up and down several times. Mixed solution was 
incubated for 20 minutes at room temperature. Then 1.8 ml of BDM was added to the 
mixed contents for a final volume of 2 ml transfection medium and a final siRNA 
concentration of 25 nM. The culture medium was refreshed with transfection medium 
and incubated cells at 37 °C in 5% CO2 for 72 h.  
2.15. HEK293 cell line culture. HEK293 cells were kindly provided by Dr. Buch. 
The frozen cells-contained vial was thaw in 37 °C water bath by gentle agitation. The vial 
was removed from the water bath as soon as the contents were thawed. The contents 
were transferred in to a fresh 10-ml tube containing 9 ml culture medium (DMEM 
supplemented with 10% FBS and 1% penicillin/streptomycin). Cells were pelleted by 
centrifugation at 800 r.p.m. for 5 min. The supernatant was discarded and cells were re-
suspended in 20 ml culture medium and seeded in T75 culture flask. Cells were kept in 
37 °C, 5% CO2 atmosphere and replaced with 10 ml fresh medium every the other day 
until the cells were ready for experiments or to be subcultured. For subculture, the 
culture medium was removed and cells were washed with sterile PBS twice, 3 ml of 0.25% 
Trypsin-EDTA solution was added to culture flask for 5 min to detach the HEK293 cells. 
After achieving complete detachment, 6 ml of culture medium was added to stop 
trypsinization. Cells were collected by centrifugation at 800 r.p.m. for 5 min and then re-
suspended in 15 ml culture medium. Aspirations were performed for about 50 times to 
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dissociate cells. Aliquots of the cell suspension were placed into new flasks or culture 
plates at a density of 6 × 103/cm2 for continue culture or 6 × 104/cm2 for overexpression. 
2.16. KV1.3 overexpression. The pJK and pJK/KV1.3 plasmids are kind gifts from 
Dr. Erich Gulbins [189]. The HEK293 cells were seeded in 6-well plates at a density of 
0.6 × 106/well and, grow overnight to reach 70-90% confluent. Lipofectamine 2000 
reagent was diluted in Opi-MEM (Invitrogen) at a ratio 5 µl: 95 µl. The pJK or pJK/KV1.3 
plasmid at amount of 2.5 µg was diluted in Opi-MEM to make the final volume at 100 µl. 
Diluted plasmids were added to each tube of diluted lipofectamine 2000 and, incubated 
at room temperature for 15 min. DNA-lipofectamine complex were applied to cells. 
Transfected-cells were collected and lysed after 48 h.  
2.17. Pull-down assay. The HEK293 whole cell lysate was prepared same as 
described above in section 2.10.. Rat brain tissue sample was homogenized in the 
isotonic sucrose homogenization buffer (2 ml) containing 0.32 M sucrose, 10 mM 
HEPES, pH 7.4, 2 mM EDTA, and a protease inhibitor cocktail (Thermo Scientific, 
Rochester, NY) in a glass grinding vessel with a motor driven Teflon pestle at 700 r.p.m..  
The homogenate was then centrifuged at 800 g for 10 min at 4 °C.  The supernatant was 
aspirated into a new tube and centrifuged at 12,000 g for 15 min at 4 °C. Pellets were 
dissolved in buffer containing 10 mM HEPEs, 1% Triton X-100 (pH 7.4) and proteinase 
inhibitor cocktail for 60 min at 4 °C with rotation.  Then the tube was centrifuged at 
12,000 g for 15 min at 4 °C.  The supernatant (membrane enriched part) was collected 
for pull down assay. GST-HIV-Tat recombinant protein (1 µg for transfected-HEK293 
and 10 µg for rat brain tissue protein) were put into protein lysate with rotation overnight 
at 4 °C.  The next day, 50 µl sepharose beads (GE health) were put into the rotating 
tube for another 3 h rotation. The beads were collected by centrifugation of 5,000 g for 2 
min and followed with three times wash by PBS.  Then the beads were added with 30 µl 
2 × loading buffer boiled 95 °C for 10 min to elute the binding protein complex. The 
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eluted samples were subjected to Western Blot for analysis of KV1.3 presence with 
specific KV1.3 antibody (1:1000, NeuroMab). 
2.18. Co-immunoprecipatation (Co-IP). For native protein Co-IP, rat brain was 
taken from 30-d-old Sprague Dawley rat and homogenized in the tissue extraction buffer 
(Invitrogen) with addition of proteinase inhibitor cocktail (Sigma). Sonication was 
performed 3 times for 15 seconds to lyse tissues. Homogenate was then projected to a 
freeze-thaw cycle for complete lysis. Then homogenate was centrifuged at 10,000 r.p.m. 
for 10 min and supernatant was collected to a fresh tube.  BCA assay was then 
performed as described to quantify protein. The amount of 1 mg protein was taken for 
co-IP. To pre-clear protein lysate, 20 µl of 50% Protein A magnetic beads (GE 
Healthcare, Sweden) were added to lysate and then incubated with rotation at 4 °C for 1 
h. Beads were pelleted by centrifugation at 1000 g for 30 s. The supernatant was 
collected to a fresh tube for immunoprecipitation. KV1.3 mouse primary antibody 
(Neuromab, 10 µl) was added to pre-cleared lysate and incubated with rotation overnight 
at 4 °C. Next day, 20 µl of Protein A magnetic beads was added and incubated with 
rotation for 30 min at 4 °C. Bead was pelleted by centrifugation at 1000 g for 30 s. The 
supernatant was discarded and pellet was washed with 500 µl tissue extraction buffer for 
5 times. Pellet was re-suspended in 1 × protein loading buffer and proceeded to Western 
Blotting for analysis of p-Src (Cellsignaling, 1:1000) presence. 
2.19. Statistics. All data are expressed as mean ± S.D. unless otherwise indicated. 
Statistical analyses were performed by student`s t test or one-way ANOVA followed by a 
Fisher`s least-significant difference test for multiple comparisons. The difference 





3.1. HIV-1 protein Tat enhancement of KV1.3 current in oligodendrocyte 
lineage cells  
To determine if HIV-1 protein Tat induces oligodendrocyte/myelin injury via activation 
of KV1.3 channels, we first examined the expression of KV1.3 current in oligodendrocyte 
cells. Two specific KV1.3 channel antagonists, MgTx and PAP, were utilized to isolate 
KV1.3-conducted K
+ currents.  Whole-cell outward K+ currents, induced by voltage-steps, 
were recorded in oligodendrocytes at the age of 14 DIV in the absence (total) and 
presence of specific KV1.3 antagonist 5 nM MgTx (IC50 ~1 nM) or 10 nM PAP (IC50 = 2 
nM [190]) in the perfusate.  KV1.3 currents were calculated by subtraction of the outward 
K+ currents recorded 20 minutes after the entrance of MgTx (MgTx) or PAP (PAP) into 
the bath chamber from the outward K+ currents recorded in the absence of MgTx or PAP 
in the perfusate (Total). These MgTx-sensitive and PAP-sensitive currents are KV1.3 
currents as illustrated at the right column (Fig. 5). These results clearly demonstrated the 
expression of KV1.3 currents in oligodendrocyte lineage cells.  
After demonstration of KV1.3 expression in the oligodendrocytes, we next tested 
effects of Tat on KV1.3 current recorded in the oligodendrocytes.  Experiments were 
carried out on two groups of oligodendrocytes, one was untreated controls (Ctrl, n = 6) 
and the other was incubated with Tat (Tat, 50 ng/ml, n = 6) for 2 h before conducting 
electrophysiology recording. Whole-cell outward K+ currents were recorded in the 
absence (Total) and presence of MgTx (MgTx). The KV1.3 (KV1.3) currents were 
calculated as described above. Incubation of the oligodendrocytes with Tat produced an 
increase of KV1.3 currents (Fig. 6A). The average peak current densities, when 
measured at +60 mV, were 61.17 ± 5.66 pA/pF in control oligodendrocytes and 94.60 ± 
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3.59 pA/pF in Tat-treated cells (Fig. 6B).  The difference is statistically significant, 




Figure 5. Expression of KV1.3 current in oligodendrocytes. Representative traces 
are whole-cell outward K+ currents recorded in oligodendrocytes before (total) and after 
super-fusion of oligodendrocytes with PAP (10 nM) or MgTx (5 nM). KV1.3-excluded 
currents showed in the middle column were recorded 20 min after super-fusion of 
oligodendrocytes with each specific KV1.3 antagonist as indicated. The KV1.3 antagonist-
sensitive currents, which represent the KV1.3 current, are calculated by subtraction of 
individual KV1.3-excluded current from corresponding total current and shown in the right 







Figure 6. Tat increased KV1.3 current on oligodendrocytes. Data were obtained from 
oligodendrocytes with (Tat) or without (Ctrl) incubation of 50 ng/ml Tat for 2 h. Panel A 
shows representative whole cell outward K+ currents recorded before (total, left column) 
and 15 min after addition of  5 nM MgTx (MgTx, middle column) to the bath. The KV1.3 
currents were then isolated by subtraction of outward K+ currents recorded in the 
presence of MgTx from the total currents (KV1.3, right column). Panel B is a summary 
bar graph illustrating average KV1.3 current density (pA/pF) obtained from 
oligodendrocytes without (Ctrl) and with Tat treatment (Tat). Note that Tat significantly 
increased KV1.3 current density measured at +60 mV. ** p < .01 vs. control Ctrl. n = 6 in 




3.2. Involvement of KV1.3 in Tat-induced oligodendrocyte injury 
It has been reported that enhancement of outward K+ current causes neural cell 
apoptosis [181, 182]. To explore whether the Tat enhancement of KV1.3 current is 
associated with Tat-mediated neurotoxic activity, we examined involvement of KV1.3 
channel in Tat-induced oligodendrocyte injury by MTT assay in the absence and 
presence of pre-added (1 h earlier) PAP (10 nM), a specific KV1.3 antagonist.  Our 
results showed that addition of Tat to the culture media for 48 h significantly decreased 
oligodendrocyte viability in a concentration-dependent manner. At the concentrations of 
50 ng/ml and 100 ng/ml, Tat reduced oligodendrocyte viability to 80.50% ± 6.81% of 
control level (p < .05) and 64.76% ± 5.83% of control level (p < .01), respectively, 
indicating that Tat induces oligodendrocyte injury in vitro (Fig. 7).  Increase of Tat 
concentrations to 200 ng/ml and 400 ng/ml did not produce further decrease of 
oligodendrocyte viability (Fig. 7). The Tat-induced decrease of oligodendrocyte cell 
viability was blocked by pre-treatment of the oligodendrocytes with PAP, demonstrating 
an involvement of KV1.3 in Tat-induced oligodendrocyte injury (Fig. 7). It has been 
shown that Tat concentration can reach as high as ∼40 ng/ml in the serum of HIV-1-
positive patients, with potential higher concentrations at local tissue sites because Tat in 
vivo might be sequestered by endogenous anti-Tat and/or by glycosaminoglycans [32, 
191]. Thus, Tat at a concentration of 50 ng/ml was considered as being physiological 
relevant and adopted for the subsequent studies reported hereinafter.  
Increasing evidence indicates that activation of KV channels is an essential pathway 
in programmed cell death [26, 84] and activation of apoptotic pathway has been 
observed in both HAND patients and Tat transgenic mice [12, 83]. Whether Tat 
enhancement of KV1.3 current contributes to Tat-induced oligodendrocyte apoptosis was 
further investigated using pharmacological and molecular genetic approaches. As 
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anticipated, addition of Tat to the oligodendrocyte culture for 48 h resulted in 
oligodendrocyte apoptosis as detected by Tunel assay. Heated Tat (boiled for 15 
minutes) had no significant effect on inducing oligodendrocyte apoptosis (Fig. 8). The 
Tat-induced apoptosis was significantly attenuated by pre-addition (1 h earlier) of 
specific KV1.3 antagonists PAP (10 nM) or MgTx (5 nM) to the culture media. In contrast, 
pre-addition of Guangxi Toxin (GxTx), a specific antagonist for K+ channel KV 2.1 which 
is also expressed in oligodendrocytes [162],  failed to block Tat-induced oligodendrocyte 
apoptosis. Addition of PAP, MgTx or GxTx each alone had no apparent effects on 
oligodendrocyte apoptosis. These results showed a clear involvement of KV1.3 in Tat-
induced oligodendrocyte apoptosis (Fig. 8). The Tat-induced oligodendrocyte apoptosis 
was also blocked through genetic knockdown of KV1.3 gene. As shown in Fig. 9, 
transfection of oligodendrocytes with KV1.3-siRNA for 72 h prevented Tat-induced 
oligodendrocyte apoptosis.  In contrast, oligodendrocytes transfected with Non-targeting 
(NT) siRNA (controls) did not block Tat-induced oligodendrocyte apoptosis.  KV1.3-
siRNA per se had no effect on oligodendrocyte cell apoptosis.  In parallel with the 
experimental data obtained with pharmacological approaches, these results further 





Figure 7. Blockade of KV1.3 attenuated Tat-induced oligodendrocytes injury. 
Oligodendrocyte cultures were exposed to Tat for 48 h at different concentrations as 
indicated with or without pre-addition of 10 nM PAP for 1 h.  Tat produced a significant 
reduction of oligodendrocyte cell viability at concentrations  50 ng/ml. Tat-mediated 
reduction of oligodendrocyte cell viability was prevented by addition of a specific KV1.3 
antagonist PAP, suggesting the Tat-mediated reduction of oligodendrocyte cell viability 
was mediated via KV1.3. Data presented were from 6 independent experiments. *p < .05 
and **p < .01 vs. control;  ##p < .01 as indicated.  
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Figure 8. Involvement of KV1.3 in Tat-induced oligodendrocyte apoptosis. 
Oligodendrocytes were exposed to Tat (50 ng/ml) for 48 h with or without pre-addition (1 
h earlier) of PAP (10 mM), MgTx (5 nM), Panel A exhibits Tunel staining (green in color) 
revealed that Tat induced oligodendrocyte apoptosis (Tat) and the Tat-induced 
oligodendrocyte apoptosis was attenuated by pre-addition of PAP (PAT + Tat), MgTx 
(MgTx + Tat) or GxTx (GxTx + Tat) to the cultures. Intact cell nuclei were visualized with 
Dapi (blue in color). In a subset of cultures, PAP (PAP), MgTx (MgTx), GxTx (GxTx) and 
heat-inactivated Tat (50 ng/ml, heated-Tat) were tested individually. Panel B shows 
average percentage of apoptotic cells from five independent experiments. There were 
nine different experimental treatments in each experiments and 10 randomly selected 
visual fields were counted for each experimental treatment. As showed in Panel b, Tat-
induced oligodendrocyte apoptosis was attenuated by either specific KV1.3 antagonist 
PAP or MgTx, but not by GxTx, a specific antagonist for KV2.1, demonstrating an 
involvement of KV1.3 in Tat-induced oligodendrocyte apoptosis. ** p < .01 vs. control; 
#p 




 Figure 9. Knockdown of KV1.3 gene prevented Tat-induced oligodendrocyte 
apoptosis. Cultured oligodendrocytes were transfected with KV1.3-siRNA for 72 h to 
knockdown KV1.3 gene or with non-targeting siRNA as a control.  Following siRNA 
transfection, 50 ng/ml Tat or heat-inactivated Tat was applied to the transfected cells for 
another 48 h. Representative PI staining images (Panel A) showed that knockdown of 
KV1.3 gene prevented Tat-induced oligodendrocyte apoptosis (siRNA-KV1.3+Tat). In 
contrast, non-targeting siRNA (NT) failed to block Tat-induced oligodendrocyte apoptosis 
(NT + Tat).  Non-targeting siRNA (NT) and KV1.3-siRNA (siRNA-KV1.3) per se had no 
apparent effect on basal levels of apoptosis. Also, oligodendrocytes transfected with NT 
and treated with Heat-inactivated Tat (NT + Heated-Tat) had no apparent effect (image 
not shown). This study was conducted in three independent experiments.  Apoptotic 
cells were counted from 10 randomly selected visual fields in each experiment with 
different experimental treatments, and then calculated and shown in Panel B that 
knockdown of KV1.3 gene prevented Tat-induced oligodendrocyte apoptosis. ** p < .01 




3.3. KV1.3 blockade prevented oligodendrocyte from Tat-induced MBP 
reduction and myelin loss. 
MBP is an essential myelin structural protein and decreased levels of MBP 
expression in oligodendrocytes reflect an impaired ability of oligodendrocytes on axonal 
myelination. Classically, MBP has three isoforms that arise from different transcription 
start sites and the protein band at 18.5-kDa is considered as the predominant isoform 
essential for CNS myelin stability [192, 193].  To determine Tat influence on MBP 
expression, we specifically examined the protein band at 18.5-kDa by Western blot 
analyses.  The same treatments as described in assessing oligodendrocyte cell 
apoptosis (Fig. 8 and 9) were employed in the experiments. The effectiveness of siRNA-
KV1.3 on knockdown KV1.3 gene was first evaluated.  As shown in Fig. 10A, 
oligodendrocytes transfected with siRNA-KV1.3 revealed the KV1.3 gene silence as 
evidenced by a significant reduction on the levels of KV1.3 protein expression when 
compared with the KV1.3 protein expression levels in non-targeting siRNA (NT)-treated 
oligodendrocytes. The involvement of KV1.3 on Tat-induced alteration on MBP 
expression was then determined through molecular genetic and pharmacological 
approaches. As illustrated in Fig. 10C, treatment of oligodendrocytes with Tat 
significantly decreased the levels of MBP expression compared to the MBP levels 
detected in non-treated controls (p < .01). The Tat-induced decrease of MBP expression 
was blocked by specific KV1.3 channel antagonists PAP and MgTx, but not by a KV2.1 
antagonist GxTx, demonstrating activation of KV1.3 underlies Tat-mediated decrease of 
oligodendrocyte MBP expression.  Such experimental results were duplicated by using 
siRNA to knockdown of KV1.3 gene (Fig. 10B).  These results showed Tat decreases 
oligodendrocyte myelination ability via KV1.3. 
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Since there were no neurons in oligodendrocyte cell cultures in above experiments, it 
was difficult to evaluate if Tat decrease of MBP expression reflects HIV-1-associated 
oligodendrocyte/myelin damage seen in HIV-1-infected individuals. Alternatively, 
cultured brain slices were utilized as an ex vivo oligodendrocyte/myelin injury model to 
address possible pathophysiological processes in an in vivo condition. Coronal brain 
slice cultures, prepared from young adult rats, were utilized to examine Tat alteration of 
myelination. Tat was added to slice culture for 72 h and specific KV1.3 antagonists were 
added 1 h prior to addition of Tat.  The treated and untreated slices were then subject to 
MBP immunostaining to examine myelin integrity and myelination was evaluated by 
western blot analyses of MBP expression. The brain regions of corpus callosum and 
striatum were selected for analyses of myelin sheath integrity.  The MBP reactivity in the 
corpus callosum was continuously aligned and exhibited an intact appearance in control 
(Ctrl) brain slices, whereas the MBP reactivity in the corpus callosum was discontinuous 
aligned and disorganized in brain slices treated with Tat (Fig. 11A left). In comparison 
with the clear and intense axonal bundles seen in the striatum of control brain slices, the 
striatum of Tat-treated brain slices showed impaired axonal bundles (Fig. 11A right). 
These abnormalities of myelinated nerve fibers and bundles were not observed in the 
slices treated with Tat combined with KV1.3 antagonists PAP and MgTx, illustrating the 
blockade of Tat-induced impairments of myelin sheaths in both brain regions by KV1.3 
antagonists. In parallel with the morphological changes observed in the corpus callosum 
and striatum, Tat decreased the levels of MBP protein expression in these two brain 
regions and the Tat-associated decrease of MBP protein expression was also blocked 
by specific KV1.3 antagonists (Fig. 11B), further support the notion that Tat induces 





Figure 10. Involvement of KV1.3 in Tat-induced oligodendrocyte MBP reduction. 
Cells were treated the same as described in Fig. 8 and 9. Data presented were from 
three independent experiments. Panel A shows a representative gel demonstrating a 
successful KV1.3 protein knockdown as a consequence of KV1.3 gene silencing. Panel B 
exhibits representative western blot results showing Tat-induced reduction on MBP 
expression was blocked by knockdown of KV1.3 gene (upper). The band densitometric 
bar graph (lower) revealed a significant Tat reduction of MBP expression and the Tat-
associated reduction of MBP expression was abolished by genetic KV1.3 silence.  Panel 
c illustrates Tat reduction of MBP expression was pharmacologically attenuated by 
specific KV1.3 antagonists, PAP and MgTx, but not by GxTx, a specific KV2.1 antagonist, 
demonstrating that Tat decrease of oligodendrocyte MBP expression via KV1.3.  
*p < .05 vs. ctrl or non-targeting siRNA (NT); ** p < .01 vs. control or NT; #p < .05 vs. Tat 









Figure 11. Tat-induced myelin injury in brain slices and its blockage by KV1.3 
antagonists. Cultured brain slices were exposed to 50 ng/ml Tat for 72 h with or without 
pre-addition (1 h earlier) of 10 nM PAP or 5 nM MgTx. Panel A, representative images of 
MBP immunofluorescence staining in corpus callosum (CC) and striatum (ST). Intact cell 
nuclei were visualized with Dapi. Tat impaired the myelin and nerve bundle integrity in 
the CC and ST.  Panel B, western blot analyses of MBP expression in brain tissues of 
the CC and the ST dissected out from cultured brain slices and lysed in tissue extraction 
buffer. Tat decreased MBP expression both in the CC (upper) and in the ST (middle). 
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Band densitometry data are shown in the bar graph (lower).  Data are expressed as 
mean ± S.E.M. after normalized to β-actin shown in each gel. Note that Tat-induced 
reduction of MBP expression was blocked by PAP and MgTx. Experiments were done in 




3.4. Tat interacted with KV1.3 channel 
Having demonstrated the involvement of KV1.3 in Tat-induced 
oligodendrocyte/myelin injury, we next sought to examine if Tat interacts directly with 
KV1.3 at protein level. For this purpose, we transfected HEK293 cells with pJK/KV1.3 
plasmid, followed by pull-down of GST or GST-HIV-Tat recombinant proteins (GST-Tat) 
with total HEK293 cell lysates. As anticipated, KV1.3 protein was successfully over-
expressed in HEK293 cells (Fig. 12A, left panel right lane) and, the recombination of 
GST-Tat was confirmed by western blot (Fig. 12B right panel). KV1.3 was precipitated by 
GST-Tat in lysates from HEK293 cells infected with pJK/KV1.3 (HEK/KV1.3), but not 
detected in pJK-infected cells (HEK/pJK, Fig. 12A right panel), suggesting Tat was 
associated with KV1.3 in HEK293 cells. The association of Tat and KV1.3 proteins was 
also detected in rat brain homogenate by the GST pull-down assay. As showed in Fig. 
12B (upper left), KV1.3 was detectable in precipitated  fraction of rat brain with addition of 
GST-Tat but not in fraction with GST per se, suggesting that Tat interacts with KV1.3 in 





Figure 12. Tat interacted with KV1.3 protein. GST-Tat recombinant protein was added 
to pJK-KV1.3 transfected HEK293 whole cell lysate or rat brain tissue homogenate for 
protein pull-down assay. Panel A, Tat interacted directly with KV1.3 expressed in 
HEK293 cells. Left in panel a is  representative blot results showing KV1.3 protein was 
successfully overexpressed in HEK293 cells  transfected with  pJK-KV1.3 (HEK/KV1.3) 
plasmids. Right in panel a shows pull-down assay demonstrating that Tat can interact 
with KV1.3 protein overexpressed in HEK293 cells. Shown in Panel B are the pull-down 
results illustrating GST-Tat interacts with KV1.3 protein in rat brain tissue lysates (left). 
The expression of KV1.3 in rat brain is showed in the lower left.  Right in panel b shows 
the bands of GST (lower bands) in both GST and Tat band (upper band) only in GST-Tat.  
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3.5. Tat enhances oligodendrocyte KV1.3 current by retarding channel 
inactivation and downregulation of channel protein phosphorylation 
Alterations in the current density of ion channels are generally attribute to three 
possible factors: changes in channel expression, promotion of channel translocation, or 
modification of channel kinetic activity. We next investigated the impact of Tat on 
oligodendrocyte KV channel kinetics of voltage dependency, which is feasible to cause 
current change in 2 h.  Primary oligodendrocytes were treated with 50 ng/ml Tat for 2 h 
before recording, and whole cell K+ currents were recorded before (Tat) and after 
addition of 5 nM MgTx to the bath solution (MgTx + Tat) for 20 min. Tat did not shift the 
activation curve of oligodendrocyte K+ currents (V1/2 = 21.52 ± 4.19 mV of control cells 
and V1/2 = 20.93 ± 4.55 mV of Tat-treated cells, p > .05), however, the inactivation curve 
shifted to the right after Tat treatment and, the shift was fully counteracted by MgTx (Fig. 
13A). This data suggest KV1.3 is primarily involved in the Tat-induced inactivation shift of 
oligodendrocyte K+ currents and, Tat may cause more slowly inactivation of 
oligodendrocyte KV1.3. 
It is known that KV1.3 channel contains several regulatory tyrosine phosphorylation 
residues at N- and C- terminus, as well as p-loop [194, 195]. Tyrosine kinases 
phosphorylate KV1.3 at these residues that cause channel inactivation, which is an 
important mechanism of KV1.3 activity regulation. We confirmed the channel 
phosphorylation by interaction of KV1.3 and tyrosine kinase p-Src (Fig. 13D), which is 
similar with previous findings that Src kinase phosphorylates KV1.3 cause current 
suppression [196, 197]. Combined that Tat affects the channel inactivation, we next 
determined the possibility that Tat changes the KV1.3 kinetics by disturbing the tyrosine 
kinase-mediated KV1.3 phosphorylating regulation. Pervanadate (PVD), a universal 
tyrosine phosphatase inhibitor, was introduced to evaluate whether Tat intervenes 
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channel phosphorylation. PVD performed to enhance channel phosphorylation thus 
sustain channel in inactive status. PVD was prepared freshly in prior to use by mixing 
sodium orthovanadate with H2O2 as described previously [179]. The oligodendrocytes 
were treated with 50 ng/ml Tat for 2 h. Currents were recorded at control and Tat-treated 
cells before and after application of PVD to bath solution at the working concentration of 
200 µM for 10 min. The shift of inactivation curve caused by Tat was neutralized by PVD 
(Fig. 13B), suggesting that Tat hinder channel inactivation by disturbing tyrosine kinase-
mediated channel phosphorylation. To confirm the phosphorylation-mediated inactivation 
shift is contributory to the current enhancement, the outward K+ current density was also 
determined with presence of PVD. Tat increased the total outward K+ currents in 
oligodendrocytes as expected and, the increase was counteracted by application of PVD 
into the bath (Fig. 13C).  
So far, we have addressed that the modification of channel kinetic activity is 
causative to enhanced KV1.3 currents. In addition to the phosphorylating regulation and 
protein-protein interaction, the potential translocation of KV1.3 channels from cytoplasm 
to plasma membrane can also induce the KV1.3 current increase in 2 h. We isolated the 
oligodendrocytes proteins to cytosol- and membrane- sections by membrane protein 
extraction kit (Biovision Incorporation), then the expression of KV1.3 in each section was 
evaluated before and after treatment with 50 ng/ml Tat for 2 h. Tat increased the 
expression of KV1.3 in cytosol section but no significant increase in membrane section 






Figure 13. Tat alteration of KV1.3 channel inactivation and channel 
phosphorylation regulation. For inactivation analysis, recoded cells were held at -80 
mV during voltage-clamping. K+ channels were pre-activated by voltage steps from the 
potential -150 mV to 60 mV with 15 mV increments and then tested at the depolarization 
pulse of 40 mV. Normalized data points were fitted with the Boltzmann equation: 
I/Imax=1/{1+exp[(V-V1/2)/k]}. Panel A, Fitted inactivation curve of each group as indicated. 
N = 8 of each group. V1/2 of Tat was -57.99 ± 2.23 mV compared with -62.39 ± 1.79 mV 






inactivation curves of each group as indicated. n = 6 of each group. V1/2 of Tat was -
49.06 ± 2.62 mV compare with -66.32 ± 1.46 mV of Ctrl. V1/2 of Tat-PVD was -65.01 ± 
4.53 mV compare with -66.60 ± 3.78 mV of Ctrl-PVD. Panel C, Mean of I-V curve of 
peak K+ current density of n = 6 of each group. ** p < .01 vs. Ctrl. Panel D, 
Representative blot shows the co-immunoprecipitation by application of KV1.3 primary 
antibody into rat brain homogenate and immunoblotted by p-Src antibody. The 
expression of p-Src in rat brain is showed in the left. Right lane shows the bands of p-





Figure 14. Tat did not promote KV1.3 translocation in 2 h. Cells were treated with 50 
ng/ml Tat for 2 h. Proteins were separated to cytosol (Cyto) and membrane (Memb) 
fraction. Panel A, representative blot of KV1.3 immunoreactivities. Panel B, data are 
normalized to β-actin. Data were obtained from 3 independent experiments. *p < .05, 





It is widely believed that HIV-1 persists in the brain despite of cART. The virus 
persistent in a latent or restricted manner in monocyte-macrophages, microglia and 
astrocytes continues to play a significant disease-inciting role. Indeed, HAND remains a 
subcortical dementia with notable evidence of affected white matter tracts within the 
corpus callosum, internal capsule and superior longitudinal fasciculus [8, 82, 91]. How 
HIV-1 brain infection causes white matter damage is not fully understood. In the present 
study, we investigated the effects of HIV-1 protein Tat on oligodendrocytes, the myelin-
forming cells in the CNS. Our results demonstrated that Tat induces oligodendrocyte 
injury via activation of voltage-gated K+ channel KV1.3. Such an effect can be blocked by 
knockdown of KV1.3 gene or by specific KV1.3 antagonists MgTx and PAP, but not by 
GxTx, a specific KV 2.1 antagonist, suggesting an involvement of KV1.3 in Tat-induced 
oligodendrocyte injury. Further studies revealed that Tat interacts with KV1.3 at protein 
level, resulting in a prolonged channel activation via a decrease of tyrosine 
phosphorylation of KV1.3 channel.  These results, to our knowledge, are the first 
demonstrations that Tat induces oligodendrocyte injury via KV1.3. 
The consensus view regarding HAND pathogenesis has been related to cerebral 
white matter damage [41, 198]. Many cellular and viral factors are involved in HIV-1-
associated brain white matter damage. Amongst them is viral protein Tat.  It has been 
shown that Tat continues to be detectable in the CSF of HIV-infected patients with well-
controlled viremia in the cART era [199].  With a broad range of actions on promoting 
inflammation and producing cytotoxic stress to various types of cells in the CNS [136], 
Tat might continue playing an important role for HIV-1-associated white matter damage 
in the cART era. Indeed, Tat has recently been shown to act on oligodendrocytes with a 
detrimental consequence [9, 12]. In an agreement with the aforementioned findings, our 
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in vitro studies revealed that Tat had a direct toxic effect on the oligodendrocytes in an 
oligodendrocyte primary culture system (purity > 85%) (Figs. 7, 8, 9). The detrimental 
effect of Tat on oligodendrocytes was validated on ex vivo studies that treatment of rat 
brain slices in culture with Tat produced myelin damage and a reduction of MBP 
expression in corpus callosum and striatum (Fig. 10). Combined with the results of 
increased apoptosis (Figs. 8 and 9), the reduction of MBP expression may reflect a 
decrease of oligodendrocyte cell numbers. These results may explain, at least in part, 
why anti-inflammatory therapies did not achieve a great benefit in HAND patients [200].  
However, Tat was found to increase oligodendrocyte cell numbers in the hilus of the 
dentate gyrus in a study on rats with intrahippocampal injection of Tat [47]. The 
discrepancy may be caused by potentially inclusion of the population of immature 
oligodendrocytes in that study [47], since proliferation of oligodendrocyte lineage cells 
could increase the probability to repair damaged myelin designedly as the response to 
Tat injection in vivo.  This notion is supported by an earlier report that mild myelin 
damage was associated with an increase in oligodendrocyte numbers, but the 
oligodendrocyte numbers decreased as damage became more severe in HIV-1-infected 
brains [90, 180]. In conjunction with a previous gross anatomical study on HIV-1-infected 
brains with demyelination which detected a reduction of corpus callosum volume [8], we 
posit that Tat induces mature oligodendrocyte injury, resulting in and loss of cerebral 
cortical white matter. Such a pathological change is concordant with the pattern of white 
matter damage observed in HAND patients.  
Studies have shown that excessive cellular K+ efflux and/or intracellular K+ depletion 
are common characteristics in early apoptosis [84, 201].  KV1.3 is positively associated 
with apoptosis in different types of cells, including retinal ganglion cell [202], 
lymphocytes [140, 203], and various cancer cells [1, 27, 174].  In agreement with these 
73 
 
studies, our results showed Tat-induced apoptosis in cultured oligodendrocytes was 
attenuated either by knockdown KV1.3 gene or by specific KV1.3 antagonists, but not by 
a KV2.1 antagonist (Fig. 8), suggesting that Tat triggers oligodendrocyte apoptosis by 
increasing K+ efflux particularly through KV1.3.  Moreover, blockade of KV1.3 rescued 
Tat-induced MBP reduction (Figs. 10, 11), indicating that KV1.3 is involved in HIV-1-
related myelin damage. However, KV1.3 inhibition only partially blocked Tat-induced 
apoptosis (Fig. 8), implying that Tat may cause oligodendrocyte injury through other 
mechanisms, such as targeting at glutamate receptors [9].  Myelin impairments may 
cause further axonal injury related to neurodegeneration in HAND, because myelinated 
axons exhibit a myelin-dependency during development [201]. Additionally, the 
increased K+ efflux from oligodendrocytes  in an in vivo condition may affect neuronal 
function through elevating the levels of extracellular K+, instead of clearing K+ released 
from neurons during axonal firings [204, 205].  An earlier study from our laboratory also 
showed that blockade of KV1.3 or knockdown KV1.3 expression in microglial cells 
attenuated Tat-induced microglia neurotoxic activity [141]. Taking together, these 
findings indicate that activation of KV1.3 plays an important role in Tat-associated 
neurotoxicity. 
 It has been shown that the activities of several different cloned KV channels are 
suppressed after phosphorylation of the channels by both receptor and non-receptor 
tyrosine kinases [206].  Indeed, there are several tyrosine residues on KV1.3 channel 
protein and different combinations of phosphorylated tyrosine residues are required for 
current suppression as consequences of different triggering signals [207-209]. Our GST-
pull down assay results showed KV1.3 presence in GST-Tat-precipitated protein complex, 
indicating a direct interaction between Tat and KV1.3 protein (Fig. 12). Such an 
interaction may cause an interruption of phosphorylation regulation of KV1.3 channel. 
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This notion is supported by experimental results that tyrosine phosphatase inhibitor PVD 
attenuated Tat enhancement of KV1.3 currents and prevented Tat-induced right-shift of 
KV1.3 channel inactivation curve (Figs. 13B and 13C).  Although we did not examine 
direct phosphorylation of KV1.3 channels due to the paucity of efficient antibody, our 
available data (Figs. 6 and 13A)  indicate that Tat may increase KV1.3 currents  by 
decrease of channel protein tyrosine phosphorylation and prolonged channel in 
activation state as revealed by a right-shift of inactivation curve (Fig. 13A).  However, the 
tyrosine kinase-associated KV1.3 channel modulation can be influenced by adaptor 
proteins through direct protein-protein association involving Src homology (SH) domains 
[195, 210]. As Tat binds to SH3 domains of Grb2 [211], it is also possible that Tat 
interacts indirectly with KV1.3 via adaptor proteins, of which Grb2 might be a potential 
candidate. In addition to protein-protein interaction and tyrosine phosphorylation 
regulation of KV1.3 channel activity, mobilization of cytoplasm KV1.3 channels to plasma 
membrane could also be possible for underlying mechanism for Tat-induced increase of 
the KV1.3 current in oligodendrocytes. We separated the oligodendrocyte proteins into 
cytosol and membrane fractions by membrane protein extraction kit (Biovision 
Incorporation), then the levels of KV1.3 in each fraction were evaluated. Tat increased 
the levels of KV1.3 in the cytosol fraction but no significant increase in membrane 
fraction (Fig. 14), suggesting the translocation of KV1.3 from cytosol to the plasma 
membrane was not involved in observed Tat-associated increase of KV1.3 current in 
oligodendrocytes.  
It is worth pointing out that the evaluations on oligodendrocyte cell viability/apoptosis 
and myelin morphology in brain slices were conducted at different time points, 48 h and 
72 h, respectively. This is because, at the same concentrations, a longer time was 
needed to generate significant morphological changes in brain slices than apoptotic 
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changes seen in primary cell cultures. It is also worth pointing out that, in addition to its 
toxic effect to mature oligodendrocytes and myelin sheaths, Tat may also induce 
disturbance of myelin maintenance via KV1.3 channels, such as oligodendrocyte 
progenitor cells proliferation and differentiation, leading to myelin/white matter 
abnormalities as seen in the brains of HIV-1-infected patients.  As basal activity of KV 
channels controls oligodendrocyte proliferation and differentiation [44, 133, 212], the 
alteration of KV1.3 channel activity by Tat may possibly disturb oligodendrocyte lineage 
cell proliferation and differentiation, and ultimately myelin maintenance processes.  In 
addition, KV1.3 was shown to play a crucial role in controlling cell cycle activation [133]. 
This may explain why PAP-treated oligodendrocytes in our studies exhibited higher cell 
viability (Fig. 7) than the control oligodendrocytes. 
In summary, our present studies demonstrated that HIV-1 protein Tat induces 
oligodendrocyte/myelin injury by enhancing outward K+ current conducted by a voltage-
gated K+ channel KV1.3 by using specific KV1.3 antagonists and siRNA knockdown of 
KV1.3 gene.  This is the first demonstration that Tat targets at oligodendrocyte KV1.3 
channels by direct protein-protein interaction and interruption of channel 
phosphorylation/de phosphorylation processes.  These findings may serve not only to 
elucidate the mechanisms underlying HIV-1-associated brain white matter damage seen 
in HIV-1-infected patients in the era of cART, but also to provide a potential target for the 
development of therapeutic strategies for amelioration of HIV/Tat-induced brain 







Chapter 3  
 
Tat impairs oligodendrocyte progenitor cell 





 HIV-1-associated neurocognitive disorder (HAND) is a subcortical disease involving 
neuronal loss and axonal demyelination. Myelin is deposited by oligodendrocytes 
through a complex process requiring oligodendrocyte progenitor cell (OPC) proliferation, 
migration, and maturation. It has been shown that OPC are susceptible to viral proteins 
such as Tat and that OPC survival and maturation are defective in HAND. Studies also 
have demonstrated that enhancement of voltage-gated K+ channels (KV) are involved in 
regulation of OPC development. Particularly, suppression of KV1.3 currents is required 
for OPC maturation. Thus we hypothesized that the HIV-1 protein Tat induces OPC 
damage and hinders OPC maturation by enhancing outward K+ current conducted by 
subtype KV1.3, contributing to HAND pathogenesis. To test this hypothesis, we studied 
the KV1.3 expression in primary cultured OPCs and, the effect of Tat on OPC apoptosis 
and maturation. KV1.3 currents and channel expression decreased within development, 
while incubation of OPC cultures with Tat increased levels of KV1.3 current density and 
channel expression as revealed by whole-cell patch clamp and RT-PCR. Tat induced 
OPC apoptosis and decreased the number of mature oligodendrocyte and, these Tat-
caused changes were prevented by 5-(4-phenoxybutoxy) psoralen, a specific KV1.3 
blocker. Our results suggest that Tat induces OPC apoptosis and maturation deficit 
through KV1.3, indicating KV1.3 as a potential target for the development of therapeutic 




Infection with HIV-1 remains a persistent and even growing health problem 
worldwide. HIV-1 invades the CNS early in the course of infection and provokes 
progressive cognitive behavioral and neurological impairments, collectively referred to as 
HIV-1-associated neurocognitive disorder (HAND) [1]. With the advent of combination 
antiretroviral therapy (cART), the number of severe HAND patients has decreased. 
However, due to a longer lifespan and drug toxocity, it is becoming apparent that 
patients suffer from protracted infection may exhibit more subtle forms of mental 
impairment of which myelin injury is one of the main causes [213]. Brains of HIV-1-
infected patients show pathological changes in the corpus callosum, which is associated 
with a significant decrease in nerve numbers and fiber density, as well as the impaired 
outer contour and decreased thickness of each single myelin sheath [8]. Because HAND 
remains highly prevalent and continues to be a significant epidemiological problem, 
research into the molecular and cellular mechanisms of HIV-induced myelin injury and 
axonal damage is pressing. 
Myelination, formed by oligodendrocytes in the CNS and Schwann cells in the PNS, 
is achieved by extending oligodendrocyte plasma membrane processes to enclose 
axons leading to formation of myelin sheath, which is an insulating sheath essential for 
saltatory propagation of electrical signal along axonal. The process of repairing 
damaged myelin is remyelination, which is required to maintain the myelin homeostasis 
and repair damage of myelin injury or loss. Remyelination involves proliferation and 
survival of oligodendrocyte progenitor cells (OPC), migration of OPCs to the damaged 
area, and maturation of OPC to mature myelinating oligodendrocytes [214]. In HIV-1 
infected brains, mild myelin damage is associated with an increase in oligodendrocyte 
number, although the number decreases with severe damage [90]. In agreement, the 
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mRNA level of transcription factor Olig2, a marker with higher expression in OPC and 
lower expression in mature oligodendrocytes [91], is elevated in  the front cortex of HIV-
1-infected patients [48]. These results indicate that OPC proliferate to repair damaged 
myelin sheath in response to HIV infection. Thus, we hypothesize that differentiation of 
OPCs into post-mitotic oligodendrocyte might be a major check-point for myelin 
maintenance and repair in HAND. 
Although the viral load is minimal in the nervous system, the transcription and 
release of viral proteins, such as Tat, from early infected cells continues over the course 
of infection [174]. Tat is a required transcription factor for HIV-1 gene expression. Tat 
has been linked to progressive development of HAND impairing the integrity of blood 
brain barrier [203, 215], activating microglia to behave cytotoxic and pro-inflammatory 
effects [198], and direct toxicity on neuronal cells [216]. Detection of Tat has been 
demonstrated in both viral-infected and uninfected oligodendrocytes in the brain of AIDS 
patients may due to its penetrability of plasma membrane [10]. Oligodendrocytes are 
susceptible to HIV-1 Tat protein involving the activation of Caspase-3 [12]. Because viral 
protein transcription continues while viral load is well controlled by cART [174, 217], Tat 
toxicity of oligodendrocyte may contribute to the fact of increased population of milder 
HAND in cART era.  
The KV channel family is the largest and a rapidly-expanding family of ion channels 
that are associated with signaling pathways required for cell survival and physiological 
activities. Accumulating evidence indicate that modulation of KV channels is a new 
approach to regulate OPC/oligodendrocyte activity. Generally, KV expression in 
oligodendrocyte lineage cells correlates with differentiation stages. Currently, the KV1 
subfamily is mostly studied in oligodendrocyte.  KV1.3 [129, 130], KV1.5, KV1.6 [129], and 
inward rectified K+ channel 4.1 [131, 132] play crucial roles in regulation of OPC 
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proliferation and maturation. In particular, KV1.3 channels play a crucial role in G1/S 
transition of proliferating OPCs [130, 133]. In addition, Kv1.3 controls cell cycle activation 
by affecting a component, C5b-9-mediated activation of AKT, thus mediate 
oligodendrocyte dedifferentiation [133]. However, the role of KV1.3 in regulation of HIV-
induced OPC maturation retardation is not fully understood. The present study 
demonstrates Tat hinders OPC differentiation and induces OPC apoptosis by increasing 




2. Materials and methods 
Information of Tat and animals, experimental procedures of OPC culture, 
electrophysiology, Western Blotting, immunofluorescence, MTT assay, and Tunel assay 
are same as described in Chapter 2 Materials and method section, unless otherwise 
complementarily described below.  
2.1. Electrophysiology. The resting membrane potentials were determined by 
zero-current potential measured shortly after achieving whole-cell recording 
conformation. The cell capacitances were read under the membrane-test function. 
Current amplitudes were measured at the peak and at 300 ms for each test potential. 
These currents correspond to the transient A-type outward K+ current (IA) and delayed 
rectified K+ current (IK), respectively.  
2.2. RNA extraction. Total RNA isolation was achieved by Trizol reagent 
(Invitrogen, Carlsbad, CA). Chloroform, isopropyl alcohol and 75% ethanol (in RNase-
free water) were all from sigma. RNase-free water was from Promega (Madison, WI).  
 OPCs were washed twice with sterile cold PBS. Trizol was provided at 1 ml to each 
well of cultures in 6-well plates. Cells were lysed by passing several times through a 
pipette. The lysate was collected in freshly-sterilized 1.5-ml tubes and then incubated for 
5 min in room temperature. Each tube received addition 0.2 ml of chloroform and then 
was capped securely. Tubes were shaken vigorously by hand for 15 seconds and 
incubated in room temperature for 3 min. Samples were centrifuged at 12,000 g for 15 
min at 4 °C. The samples were then separated into 3 phases after centrifugation: lower 
red phase, protein-enriched interphase, and a colorless upper aqueous phase that 
contained RNA. Approximately 0.5 ml of the upper phase of each sample was carefully 
transferred into fresh tubes. The same amount of 0.5 ml of isopropyl alcohol was added 
to each tube to precipitate the RNA. Samples were incubated at room temperature for 10 
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min. Centrifugation was then performed at 12,000 g for 10 min at 4 °C. The RNA 
generally formed a gel-like pallet at the bottom of tubes. The supernatant was removed 
and, 1 ml 75% ethanol was added to each tube to wash the RNA. Samples were 
preceded to vortex and centrifuged at 7,500 g for 5 min at 4 °C. 
 The RNA isolation was finally achieved by discarding the supernatant and drying the 
pallet in room temperature for about 5 min. RNA was dissolved in 12 µl RNase-free 
water by passing them through a pipette. The amount of 2 µl RNA of each sample was 
taken for RNA concentration determination. The rest was stored at -80 °C for further 
reverse transcription. RNA concentration was determined by Nanodrop 2000.  
2.3. Reverse transcription-PCR. Reverse transcription was accomplished with a 
SuperScript III first-strand synthesis kit (Invitrogen). The amount of 2 µg of each RNA 
sample was taken and balanced the volume of to 8 µl by RNase-free water for every 
sample, followed by addition of 1 µl oligo-dT primer and 1 µl dNTPs to each sample. The 
cDNA synthesis mix was prepared in a separate tube by mixing 2 µl of 10 × RT buffer, 4 
µl of 25 mM MgCl2, 2 µl of 0.1 M DTT, 1 µl of RnaseOUT, and 1 µl of SuperScript III RT 
(10 µl total) for each sample. The prepared mix was kept on ice. 
 The sample (RNA + primer + dNTPs) was projected onto the thermal plate of PCR 
machine (Eppendorf RealPlex2). The program was set as 65 °C for 5 min, pause, 50 °C 
for 50 min, 85 °C for 5 min, pause, 37 °C for 20 min, hold at 4 °C. After reverse 
transcription program started, the samples were taken out at the first pause and placed 
on ice for at least 1 min. Prepared cDNA synthesis mix (10 µl) was added to each 
sample. At the second pause, 1 µl of RNase H was provided for each sample.  
 Reactions containing cDNA from reverse transcription, unique primer pairs and PCR 
master mix 2× (Promega) were systematically performed for PCR amplification. Primer 
sequences were designed according to the rat cDNA: KV1.3 forward primer, GTA CTT 
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CGA CCC GCT CCG CAA TGA, reverse primer, GGG CAA GCA AAG AAT CGC ACC 
AG; GAPDH forward primer, TCA AGA AGG TGG TGA AGC AG, reverse primer, AGG 
TGG AAG AAT GGG AGT TG. PCR cycles were performed as follows: initial 5 min at 
95 °C, then 30 cycles of 95 °C (15 s), 55 °C (30 s), and 72 °C (45 s), followed by 10 min 
at 72 °C for completion of extension. 
2.4. Statistics. All data are expressed as mean ± S.D. unless otherwise indicated. 
Statistical analyses were performed by student`s t test or one-way ANOVA followed by a 
Fisher`s least-significant difference test for multiple comparisons. The difference 









3.1. Developmental changes of OPC/oligodendrocyte resting membrane 
properties 
Whole-cell voltage-clamp studies were performed on cells that had been cultured 12-
21 d (2-11 d after isolated from mix glial culture). In order to avoid electrical coupling 
between adjacent cells, the investigations reported in the present study were confined to 
cells that extended processes but did not contact with neighbor cells. Table 1 lists 
resting membrane potential and membrane capacitance that were observed during 
development in OPC/oligodendrocyte culture. Generally, the resting membrane potential 
changed toward negative within time during OPC development. However, resting 
membrane potential of mature MBP+ oligodendrocytes remained similar compared with 
late GalC+ OPCs. Membrane capacitances were larger in GalC+ and MBP+ cells than 
those in NG2+ OPCs. The membrane capacitances varied from 7.05 pF in a cell had 
bipolar morphology to 25.40 pF in a cell that developed multiple processes.  
3.2. K+ currents in oligodendrocyte lineage cells at different developmental 
stages  
To investigate the activity of KV channels in oligodendrocyte lineage cells, whole-cell 
K+ currents in OPCs/oligodendrocytes were recorded at different developmental stages. 
OPCs were recorded at three ages. Early stage of NG2+ OPCs were recorded at 14 d 
and 17 d (NG2+ 14 d, NG2+ 17 d) respectively. Late stage of GalC+ OPCs were recorded 
at 19 d (GalC+). MBP+ cells were recorded at 21 d to represent mature oligodendrocytes 
(MBP+). At an early stage of 14 d, NG2+ cells expressed relatively high level of outward 
K+ currents. However, the current density of IA was decreased by 44% as the cells 
differentiated to MBP+ oligodendrocytes. In contrast, IK did not show significant changes 
during OPC development (Fig. 16).   
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Table 1 Resting membrane properties of OPCs/oligodendrocytes 




NG2+ 12    -49.89 ± 16.10 12.23 ± 2.01 10 
 13    -47.06 ± 11.60 11.34 ± 3.48 10 
 14    -54.33 ± 12.10 15.74 ± 4.76 16 
 15    -60.02 ± 10.89 13.78 ± 2.80 9 
 16    -64.62 ± 5.71 13.92 ± 3.70 9 
 17    -65.57 ± 5.92 15.06 ± 3.67 15 
GalC+ 18    -66.47 ± 3.87 17.44 ± 4.50 21 
 19    -67.37 ± 2.24 18.52 ± 6.49 16 






Figure 16. Developmental changes of whole-cell K+ currents in oligodendrocytes. 
Panel A, representative current traces recorded during depolarizing and hyperpolarizing 
pulses are shown in 14 d NG2+ cells (NG2+ 14 d, n = 16), 17 d NG2+ cells (NG2+ 17 d, n 
= 15), GalC+ cells (GalC+, n = 8), MBP+ cells (MBP+, n = 15). To record total currents, 
cells were held at -80 mV and pulses were applied to various test potentials for 300 ms 
as shown in the upper voltage-clamp protocol (not proportional to the current traces in 
duration). IA was eliminated by holding the membrane potential at -40 mV to record IK, as 
shown by the clamp protocol in the second row. IA was derived by a subtraction of IK 
from total K+ current and mean data are summarized in panel C. Current density-voltage 
relationship of IK (B) and IA (C) in each group. ** p < .01 NG2
+ 14 d vs. MBP+ at +60 mV 
voltage steps.  
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3.3. Involvement of KV1.3 in Tat-induced K
+ current enhancement  
 It is known that KV1.3 is expressed at both mRNA and protein levels in OPCs and 
contributes to the generation of the IA component [130]. By giving that gradual decrease 
of outward K+ currents within maturation, we next determined if KV1.3 is responsible for 
the observed change in outward K+ currents. The mRNA expressions of KV1.3 at 
different developmental stages and the effect of Tat on KV1.3 expression were examined 
by RT-PCR. At the three tested stages, KV1.3 expression was highest in 14 d NG2
+ 
OPCs and the expression decreased within development. However, application of Tat to 
OPC culture for 48 h increased KV1.3 expression in OPCs compared with that in same 
age of OPCs (17 d NG2+ OPCs, Fig. 17). Corresponding results of KV1.3 currents were 
revealed by electrophysiological studies. The specific KV1.3 blocker, PAP, was used to 
isolate KV1.3-conducted K
+ currents in OPCs by subtraction (as described in Chapter 2). 
KV1.3 currents decreased within development in late OPCs compare with the early NG2
+ 
OPCs at 14 d (78.31 ± 16.42 of NG2+ 14 d vs 54.86 ± 12.36 of GalC+ OPC, p < .05). 
Treatment of 50 ng/ml Tat for 2 h increased KV1.3 currents (114.97 ± 22.35) compared 
with control NG2+ OPCs at 14 d (Fig. 18). These data suggest that KV1.3 is involved in 
the decrease of total outward K+ currents during development and Tat increased KV1.3 





Figure 17. Effect of Tat on OPC KV1.3 mRNA expression. Cells were collected at 
different ages as indicated. For Tat-treated OPCs (Tat-NG2 17 d), Tat was applied to 
culture at 15 d for 48 h and then OPCs was collected at 17 d. Data represent results 
from three independent experiments. Panel A, representative gel demonstrating mRNA 
expression of KV1.3. Band densities were normalized to GAPDH and summarized in 
panel B. KV1.3 mRNA expression decreased in NG2 17 d and GalC cells compare with 
NG2 14d. Tat up-regulated KV1.3 mRNA expression in NG2 17 d cells. * p < .05, # p 







Figure 18. Developmental change of KV1.3 currents and alteration caused by Tat. 
Data are shown for OPCs cultured for different days as indicated. Tat was applied to 14 
d OPCs for 2 h in prior of recording (Tat-NG2+ 14 d). After recordings were obtained in 
normal bath solution, 10 nM PAP was perfused into the cell chamber. KV1.3-excluded 
currents were recorded at 20 min after perfusion. Isolated KV1.3 currents were obtained 
by subtraction of KV1.3-excluded current from total current. Panel A shows 
representative current traces. The voltage protocol used to generate K+ is shown in inset. 
Panel B summarizes the KV1.3 current density at +60 mV. n = 6 of each group.  * p < .05, 





3.4. KV1.3 involved in Tat-induced OPC apoptosis and maturation retardation 
 Although the typical cells in brain infected by HIV-1 are microglia in the CNS [218], a 
recent report has shown that Tat decreases OPC cell viability [9]. As previously noted, 
Tat has been detected in serum and CSF at a concentration between 2-40 ng/ml in HIV 
patients, however, this concentration could be under-estimated in local tissue [184, 185]. 
Since Tat cause oligodendrocyte apoptosis through KV1.3, we sought to determine if Tat 
cause OPC apoptosis at a similar manner. To explore the effect of Tat on OPC 
apoptosis and the involvement of KV1.3 channels, Tat was applied to 15 d OPCs at a 
dose of 50 ng/ml with (PAP + Tat) or without (Tat) pre-addition of PAP (1 h) for 48 h. 
Apoptosis was assessed at the OPC age of 17 d by Tunel staining. Exposure of OPCs to 
50 ng/ml Tat increased the percentage of apoptotic cells by approximately 2-fold over 
non-treated control (Ctrl) and such an increase was prevented by PAP (Fig. 19).  
 As noted in the introduction to Chapter 1, maturation of OPCs to oligodendrocytes is a 
challenge point for myelin maintenance and remyelination in HAND. Besides Tat-
induced OPC toxicity, alterations in OPC maturation is potentially contributory to 
observed myelin damage in HAND. We examined whether Tat hinders OPC maturation. 
GalC+ OPCs were treated with 25 ng/ml Tat, which is the dose did not cause OPC 
apoptosis (Data not shown), while transferring cells into differentiating medium with or 
without pre-addition of PAP (1 h). After 48 h, the cells in differentiating medium (Ctrl), 
differentiating medium contained Tat (Tat), and differentiating medium contained PAP 
and Tat (PAP + Tat) were projected to maturation analysis. The maturation was 
determined by percentage of MBP+ cells and NG2+ cells as revealed by 
immunofluorescence. Tat dramatically decreased the population of MBP+ cells from 
90.91% ± 21.18% (Ctrl) to 44.44% ± 8.92% (Tat), and sustained more cells in NG2+ 
OPC status (48.15% ± 8.62% of Tat vs 6.06% ± 3.87% of control). Pre-treatment of PAP 
92 
 
partially prevented the MBP+ cell number decrease, suggesting Tat induce OPC 




Figure 19. Involvement of KV1.3 in Tat-induced OPC apoptosis. 10 nM PAP was 
added to the NG2+ OPCs at 15 DIV for 1 h, followed by application of 50 ng/ml Tat (PAP 
+ Tat) for 48 h. In a subset of cultures, 50 ng/ml Tat (Tat) or 10 nM PAP (PAP) alone 
was added to culture media for 48 h. Panel A shows Tunel staining (green) to identify 
apoptotic cells. Intact cell nuclei were visualized with Dapi (blue). Mean data are from 10 
fields of each treatment from 3 independent experiments. Apoptotic percentage of each 
group is summarized in panel B. Tat increased OPC apoptosis, which was prevented by 





Figure 20. Suppression of KV1.3 prevented Tat-induced maturation retardation. 
While OPCs being transferred to differentiating medium at 19 DIV, PAP was pre-applied 
to OPC for 1 h, with (PAP + Tat) or without (PAP) following co-presence of 25 ng/ml Tat 
for 48 h. In a subset of cultures, cells were in parallel transferred in normal differentiating 
medium (Ctrl), or differentiating medium contained 25 ng/ml Tat (Tat). Panel A, 
representative fields show MBP staining (green) an NG2 staining (red) result as a 
measurement of OPC maturation, with cell nuclei visualized using Dapi stain. 10 visual 
fields were analyzed for each of three independent experiments. Panel B, Tat induced 
MBP+ cell number decrease was prevented by PAP. ** p <.01 vs. control (Ctrl); # p <.05 
vs. Tat group; magnification was 400 ×.  
95 
 
4.  Discussion 
Presently we show that the HIV trans-activator Tat induces OPC injury and hinders 
OPC maturation using a mechanism involving KV1.3. There are two novel findings: 1) 
direct induction of OPC apoptosis by HIV Tat, which is independent of the immune 
system, and 2) KV1.3 channels play an essential role in Tat-induced OPC apoptosis and 
maturation retardation.  
In this study, we described the resting membrane properties of decreased resting 
membrane potential and capacitance of OPCs as well as the total K+ currents within 
development. The developmental IA declining in OPCs was accompanied with the 
decrease of KV1.3 mRNA expression (Fig. 17) and decreased KV1.3 currents (Fig. 18). 
This finding is similar with results previously reported that outward K+ currents are larger 
during early stages of development [129, 130, 219, 220]. Moreover, the subtracted 
current traces shown in Fig 18 imply that KV1.3 is transient-activated, which corresponds 
to IA currents. These data suggest the regulation of KV1.3 expression is at least partially 
responsible for the IA changes during development (Fig. 17). However, the resting 
membrane potential becomes more negative within time, indicating that KV1.3 is not a 
primarily contributory to the maintenance of OPC resting membrane potential. Previous 
study demonstrated the resting membrane potential did not alter in oligodendrocytes at 
the age from 1-14 d in primary culture [155]. The discrepancy between this early result 
and ours is uncertain. However, it may due to the different animal model and culture 
conditions. Their works were done in GalC+ oligodendrocytes isolated from the lamb 
brains and cultured in DMEM supplemented with 20% horse serum, whereas ours were 
isolated from rat brains and cultured in medium as described in Method. In addition, the 
Na+ or Ca2+ channel inhibitor was not present in recording solutions. There was no Ca2+-
like current observed, and Na+- current was recorded in less than 10% of the whole 
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recorded cell population. It is possible that the Na+- current-expressed cells are neural 
progenitor cells.  
Our results show that Tat causes apoptosis in primary culture (Fig. 19), suggesting 
that Tat perform direct toxicity on OPCs. These findings are consistent with research 
demonstrating Tat decreases OPC cell viability by targeting at NMDA receptor [9]. The 
consensus view regarding the pathogenesis of HAND is generated by direct and indirect 
models as described in Chapter 1 Introduction 1.2., of which are briefly direct toxicity and 
consequences of inflammatory response caused by neurotoxins secreted from infected 
macrophages, microglia, or astrocytes. Most studies suggest Tat causes neuronal 
function deficits predominantly by inducing CNS inflammation (indirect model) in HAND. 
However, HAND patients given cART with adjunctive “anti-inflammatory” agents do not 
attain greater benefits compared with those with cART only [221], suggesting 
inflammation maybe not the primary factor drives HAND pathogenesis in patients on 
cART. Because Tat transcription continues in these patients with good access with 
cART, Tat-performed direct toxicity on OPCs provide a potential mechanism for 
observed myelin damage in cART era [222]. Regarding the concept of increased efflux 
of K+ in programmed cell death [84] [223], our recent research has focused attention on 
the role of KV channelopathies in HAND pathology. In an earlier publication from our 
laboratory, we demonstrated that blockade of KV1.3 or knockdown KV1.3 expression in 
microglial cells eliminated neuronal apoptosis triggered by exposure to supernatant from 
Tat-containing microglia [141]. We show that Tat exposure leads to an up-regulation of 
KV1.3 mRNA (Fig. 17) expression and amplification of KV1.3 currents (Fig. 18). Tat-
induced apoptosis in cultured OPCs was decreased in the presence of PAP (Fig. 19), 
suggesting that Tat may trigger OPC apoptosis by amplifying K+ efflux through KV1.3 
(Fig. 18, and 20). 
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Controversial results have been reported in OPC cell fate in HIV-related 
pathogenesis. The mRNA levels of transcription factor Olig2, which is expressed to 
higher levels in OPC and lower levels in mature oligodendrocytes [91], are elevated in  
the front cortex of HIV patients [48], may due to increased OPC proliferation for repairing 
damaged myelin sheath in response to HIV infection. However, in another research, Tat 
exposure reduces the population of Olig2+ OPCs, but progenitor survival is unaffected 
[85], suggesting the proliferation was interrupted. Overall, as mentioned in Chapter 1, 
HIV-1 infection or viral protein exposure appears to incline NPC fate toward production 
of glia/astroglia at the expense of neurons and/or oligodendrocytes [85, 93, 94]. Thus we 
hypothesized OPC maturation is the key point for myelin maintenance and remyelination 
in HAND. Studies of genetically altered expression of KV channels in oligodendrocytes 
suggest that basal activity of KV channels directly controls proliferation and differentiation 
[183, 212]. Immunocytochemical staining of oligodendrocyte lineage cells acutely 
isolated from tissue slices demonstrated that expression of KV1.3 and KV1.5 subunits 
was higher in NG2+ and O4+ (late OPC maker) OPCs than in mature O1+ 
oligodendrocytes. In parallel, the expression of the same subunits within the NG2+, O4+, 
and O1+ populations had the same pattern as that of cyclin D, suggesting that KV1.3 is 
developmentally regulated with progression through the oligodendrocyte lineage [130]. 
Tat exposure decreases the population of MBP+ cells (Fig. 20) and KV1.3 blockade 
restrain Tat-induced OPC maturation deficit, suggesting OPC maturation is impaired in 
HAND and, Tat may act through KV1.3 channel to achieve dysregulation of OPC 
maturation. It is worth noting that neuronal axons were not present in pure 
OPC/oligodendrocyte culture; thus, we were not able to detect myelination. Maturation of 
oligodendrocytes in vitro is not equal to successful myelination in vivo.  
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Pathogenesis of myelin injury-related cerebral WM damage in HAND recently 
attracted attention [41, 224]. HIV-1-associated myelin injury has been attributed to 
effects of inflammatory response and BBB damage. However, in present study, we show 
Tat directly target at OPC to cause cell apoptosis and maturation retardation; the 
presence of PAP mitigates Tat-induced apoptosis and maturation retardation by 
inhibiting enhancement of KV1.3 currents. Collectively, these findings serve to better 
understand the myelin damage and repair processes in HAND, and support the role of 









Plasma gelsolin protects HIV-1 gp120-induced 








Plasma gelsolin (pGSN), a secreted form of gelsolin, is constitutively expressed 
throughout the central nervous system (CNS).  Neurons, astrocytes and 
oligodendrocytes are the major sources of pGSN in the CNS.  It has been shown that 
levels of pGSN in cerebrospinal fluid (CSF) are decreased in several neurological 
conditions including HIV-1-associated neurocognitive disorders (HAND).  Although there 
is no direct evidence that a decreased level of pGSN in CSF is causally related to the 
pathogenesis of neurological disorders, neural cells, if lacking pGSN, are more 
vulnerable to cell death. To understand how GSN levels relate to neuronal injury in 
HAND, we studied the effects of pGSN on HIV-1 gp120-activated outward K+ currents in 
primary rat cortical neuronal cultures. Incubation of rat cortical neurons with gp120 
enhanced the outward K+ currents induced by voltage steps and resulted in neuronal 
apoptosis. Treatment with pGSN suppressed the gp120-induced increase of delayed 
rectifier current (IK) and reduced vulnerability to gp120-induced neuronal apoptosis. 
Application of Guangxitoxin-1E (GxTx), a Kv2.1 specific channel inhibitor, inhibited 
gp120 enhancement of IK and associated neuronal apoptosis, similar effects to pGSN. 
Western blot and PCR analysis revealed gp120 exposure to up-regulate Kv2.1 channel 
expression, which was also inhibited by treatment with pGSN. Taken together, these 
results indicate pGSN protects neurons by suppressing gp120 enhancement of IK 
through Kv2.1 channels and reduction of pGSN in HIV-1-infected brain may contribute to 
HIV-1-associated neuropathy. 
Keywords: Cortical neurons; Kv channels; HIV-1gp120; Neuronal injury; Plasma 




Approximately half of the HIV-1-infected patients develop neurocognitive 
impairments [225]. With the advent of antiretroviral therapy (ART), the morbidity and 
mortality resulting from HIV-1 infection has been lessened. However, the incidence of 
HIV-1-associated neurocognitive disorders (HAND) continues and, due to the longer 
lifespans of treated patients and ART drug toxicity, the prevalence may actually be 
increasing [174, 226-228].  Although productive HIV-1 infection of neuronal cells has not 
been demonstrated, it is well accepted that neurons are affected by HIV-1 through 
indirect mechanisms [229-231]. These include the release of soluble neurotoxins from 
HIV-1-infected and immune competent mononuclear phagocytes (perivascular brain 
macrophage and microglia), leading to neuronal dysfunction and injury [229, 232].  As 
noted in Chapter 1, such neurotoxins include, but not limited to, proinflammatory 
cytokines, chemokines, excitatory amino acids, and viral proteins (gp120 and Tat), which 
can injure or kill neurons [233].  In particular, the envelope protein gp120 has been 
shown to be lethal to neurons in culture through alterations in signal transduction and 
excitotoxic influx of Ca2+ [234-236]. For these reasons we chose to use gp120 to further 
investigate the mechanisms underlying HAND pathogenesis in our primary neuronal 
culture system. 
Gelsolin (GSN) is an actin-binding protein best-known for its modulation of cell 
motility and secretion, is constitutively expressed throughout the CNS and particularly 
concentrated in neuronal growth cones. This protein exists in two isoforms, cytoplasmic 
gelsolin (cGSN) and plasma gelsolin (pGSN) [237]. Both isoforms are functionally similar 
and encoded by a single gene on chromosome 9 [238, 239]. In addition to its widely 
recognized function as a cytoplasmic regulator of actin organization, accumulating 
evidence suggests GSN activity prevents neuronal apoptosis in multiple ways [240], 
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including through the facilitation of voltage-dependent Ca2+ channel (VDCC) and NMDA-
channel rundown following exposure to excitotoxic stimuli, thereby reducing cytosolic 
Ca2+ overload [241, 242]. Proteomic studies have revealed decreased pGSN levels in 
CSF of HIV-infected individuals with cognitive disturbance [243]. In addition, altered 
pGSN levels have been noted in other neurological conditions [244-246], such that 
pGSN is being considered as a biomarker for certain neurodegenerative disorders [246-
248].  In general, GSN has been found neuroprotective and is now being considered as 
a potential treatment modality in several diseases characterized by neuronal injury [244, 
245, 248-251]. 
K+ channels necessarily contribute to the process of apoptosis. Regardless of the 
diverse external and internal stimuli that trigger cell apoptosis, enhanced K+ efflux has 
been shown to be an essential mediator of apoptotic cell volume decrease, downstream 
caspase activation, and DNA fragmentation [84]. In previous experiments, our laboratory 
has confirmed the association of rat cortical neuron apoptosis and increased K+ channel 
currents in models of HAND [143, 144, 252]. While several Kv channel subtypes have 
been implicated in cortical neuron apoptosis, including Kv2.1 [152], Kv1.1 [253], Kv3.4 
[153], Kv4.2, and Kv4.4 [154], the specific subtype involved in HAND pathology and the 
mechanism underlying its dysfunction remains to be definitively characterized. 
Collectively, these observations lead us to investigate the protective potential of pGSN 
against gp120-induced neuronal injury and to determine the function of specific Kv 




2. Experimental Methods 
2.1. Materials  
HIV-1gp120 IIIB was purchased from Immunodiagnostics, Inc. (Woburn, MA).  
Aliquots of gp120 were kept as 100 nM stock solution at -80 C. The stock solution was 
diluted to desired concentrations with artificial cerebrospinal fluid (ACSF) 2-5 min before 
test. Gelsolin (recombinant human plasma isoform) was purchased from Cytoskeleton, 
Inc (Denver, CO).  All chemicals, unless otherwise specified, were from Sigma-Aldrich 
(St. Louis, MO). 
2.2. Animals 
Pregnant Sprague-Dawley rats were purchased from Charles River Laboratories 
(Wilmington, MA).  Animals were housed at a constant temperature (22°C) and relative 
humidity (50%) under a regular light-dark cycle (light on at 7 AM and off at 5 PM) with 
free access to food and water. Animal use procedures were strictly reviewed by the 
Institutional Animal Care and Use Committee (IACUC) of the University of Nebraska 
Medical Center (IACUC No. 00-062-07). 
2.3. Rat cortical neuron preparation and culture 
Neurons were isolated from cortex tissue of E18 fetal Sprague-Dawley rats. Culture 
dishes or plates were coated with poly-D-lysine (1mg/ml) for 1 h at 37 °C in prior to 
primary culture. All tools were autoclaved.  
Firstly, pregnant rat was anesthetized by isoflurane and, then cut through skin and 
muscle with a pair of scissors to expose the uterus, intestines, and embryos.  Embryos 
(in amniotic sac) were taken out carefully and placed into 10 cm- petri dish filled with 
cold HBSS. Embryos were taken from amniotic sac and placed to a fresh petri dish with 
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cold HBSS. Next, embryos were decapitated with large scissors and the heads were 
placed in a spate 10 cm-petri dish filled with cold (HBSS).  
Microdissecting scissors was used to carefully cut skin and the skull along the 
midline from neck toward the nose. Brain was then taken out with a spatula and placed 
to another petri dish contained cold HBSS.  
The meninges were removed with forceps under a dissection microscope. Cortex 
tissue was dissociated by cutting the brain to two hemispheres, followed by removing 
hippocampus and olfactory bulbs. The tissue was then incubated in 0.25% trypsin and 
200 U DNase contained in HBSS at 37 °C for 15 min. FBS was applied to tissue 
suspension to stop trypsinization and then homogenate was transferred to a 50 ml tube. 
The contents were pipetted one time to separate any tissue block. The tissue 
suspension was next collected into a clean 50 ml-tube and centrifuged at 1500 r.p.m for 
10 min. The supernatant was removed and 20 ml DMEM was added to suspense the 
remained cells/tissues by triturating cells/tissue for about 20 times. The remaining tissue 
suspension was passed through nylon mesh with pore diameter size of 100 µm and 40 
µm. Cells were collected by centrifugation at 1500 r.p.m for 10 min.  
Isolated cells were then suspended in neurobasal media (Gibco by Life Technologies) 
supplemented with 2% B27, 1% penicillin/streptomycin, 0.2% FBS, and 0.25 mM L-
glutamine (Invitrogen by Life Technologies), and seeded either in 60 mm dishes at 2.5 x 
106 cells/dish, 0.2 x106 cells/well in 12 well plates containing 15 mm diameter coverslips, 
or in 48-well plates at 0.05 x 106 cells/well. Cultures were maintained in supplemented 
neurobasal media for 8-12 days with half media change every 4 days. The purity of 
neuronal cells was determined to be >90% (Fig. 21) by staining with microtubule-






Figure 21. Purity of cortical neuronal cultures. View of neurons stained with Map2 
(red).Cell nuclei are visualized wih DAPI DNA stain.  Neuronal purity >90%.  
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2.4. MTT assay 
Cell viability was assessed by MTT assay. Neurons were cultured in 48-well plates 
for MTT assay to minimize discrepancies between replicates. The MTT stock solution 
was prepared in sterile PBS at concentration of 5 mg/ml (10 ×) and store at -20 °C. The 
working solution was made by diluting the stock MTT solution 10 times with neurobasal 
media without supplements. Pre-treated cells were exposed to 300 µl of neurobasal 
media contained 500 µg/ml MTT (Sigma-Aldrich) for 2 h at 37 ºC. The MTT solution was 
discarded and replaced with 150 µl dimethyl sphingosine (DMSO). Cells were then 
shaken for 15 min at 200 r.p.m for completed lysis. The dissolved solution was 
transferred of 100 µl from each well to a 96-well plate and, 96-well plate was eventually 
placed to a plate reader and tested the optical density at 560 nm. 
2.5. Tunel assay 
Neuronal apoptosis was evaluated by using a Fluorescein In Situ Cell Death 
Detection Kit (Roche Applied Science, Indianapolis, IN).  Briefly, Neurons grown on the 
poly-D-lysine-coated coverslips were washed twice with PBS and fixed in 4% 
paraformaldehyde (PFA) for 1 h at room temperature. Then cells were permeabilized by 
incubation with 0.1% Triton X-100 for 30 min. Cover slips were washed 5 min × 3 times 
with PBS. Tunel reaction mixture was made by adding 1 part label solution to 50 parts 
enzyme solution. The reaction mixture was applied onto clean Para film as 30 µl-drops 
and, cover slips were flipped onto reaction mixture solution spots and incubated for 90 
min at 37 °C. After washing, coverslips were mounted in vectashield mounting medium 
with Dapi stain (Vector Laboratories, Burlingame, CA) and cells were visualized by a 
fluorescent microscope. Apoptosis was assessed in each of three experiments by 
examining 10 microscopic fields per experimental group. The percentage of apoptotic 
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neurons was determined based on Tunel-positive cells normalized to Dapi-stained nuclei 
in 3 independent experiments. 
2.6. Electrophysiology 
Whole-cell recordings were made on neurons seeded on glass cover-slips at 9-12 d. 
Recording electrodes, pulled from borosilicate glass micropipettes (WPI Inc. Sarasota, 
FL) with a P-97 micropipette puller (Sutter Instruments, Novato, CA),  had a resistance 
of 5.0–8.0 MΩ when filled with intracellular solution contained (in mM): 120 K-gluconate, 
10 KCl, 5 NaCl, 1 CaCl2, 2  MgCl2, 11 EGTA, 10 HEPES, 2 Mg-ATP and 1 GTP, 
adjusted pH to 7.3 with KOH.  The extracellular solution was artificial cerebrospinal fluid 
(ACSF) contained (in mM) 140 NaCl, 5 KCl, 2.5 CaCl2, 10 HEPES and 10 glucose,  
adjusted pH to 7.4 with NaOH. Tetrodotoxin (TTX, 1µM) and CdCl2 (0.2 mM) were 
added to the ACSF to block voltage-gated Na+ and Ca2+ channels, respectively. Stock 
solutions of 4-Aminopyridine (4-AP) and tetraethylammonium (TEA) were prepared in 
deionized water and diluted to working concentrations (4-AP 5mM, TEA 40mM)  with 
ACSF in order to block A-type transient outward K+ current (IA) or delayed rectifier 
outward K+ current (IK).  After establishment of the whole-cell patch configuration, the 
cells were allowed to stabilize for 3-5 min before tests. The recorded cells were held at -
80 mV during voltage-clamping. Whole-cell outward K+ currents were generated by 
voltage steps from the holding potential -80mV to +80mV in increments of 20mV. 
Current amplitudes were measured at the initial peak and at 300 ms and current 
densities (pA/pF) were calculated by dividing the amplitudes by the whole cell 
capacitance. Junction potential, pipette resistance were corrected and cell capacitance 
were compensated (~70%).  Current signals were filtered at 1 kHz and digitized at 5 kHz 
using Digidata 1440A digitizer (Molecular Devices).  The current and voltage traces were 
displayed and recorded in a computer using Clampex 8.2 (Molecular Devices).  
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All experiments were done at room temperature (22-23°C). In prior to recording, the 
bathing solution was oxygenated (bubbled with 95% O2 and 5% CO2) for 30 min. The 
neuronal cells were identified by their morphology (triangular shaped) and their firing of 
action potentials in response to a depolarizing current impulse. Data were analyzed by 
Clampfit 8.2 (Molecular Devices) and graphed using Origin 8.5 (OriginLab, Northampton, 
MA).  For bar graphs illustrating current densities, the instantaneous IA and steady-state 
IK generated by a voltage step from -80mV to +80mV were measured and the current 
density was then calculated by dividing the current and expressed as pA/pF.   
2.7. RT-PCR 
 The total RNA isolation was completed with Trizol reagent (Invitrogen). Reverse 
transcription was performed on 1-2 µg of the RNA sample with a SuperScript III first 
strand synthesis kit (Invitrogen) using the oligo-dT primers.  
 Pre-treated neurons were washed twice with sterile cold PBS, followed by addition of 
1 ml Trizol to each well of culture in 6-well plate. Cells were lysed by passing cells 
several times through a pipette. The lysate was collected in freshly-sterilized 1.5 ml 
tubes and then incubated for 5 min in room temperature. Each tube received addition 0.2 
ml of chloroform and was capped securely. Tubes were shaken vigorously by hand for 
15 seconds, and then incubated in room temperature for 3 min. Samples were 
centrifuged at 12,000 g for 15 min at 4 °C. Following centrifugation, the samples were 
then separated into 3 phases: lower red phase, and protein-enriched interphase, and a 
colorless upper aqueous phase that contained RNA. Approximately 0.5 ml of the upper 
phase of each sample was carefully transferred into fresh tubes. The same amount of 
0.5 ml of isopropyl alcohol was added to each tube to precipitate the RNA. Samples 
were incubated at room temperature for 10 min. Centrifugation was then performed at 
12,000 g for 10 min at 4 °C. The RNA generally formed a gel-like pallet at the bottom of 
109 
 
tubes. The supernatant was removed and, 1 ml 75% ethanol was added to each tube to 
wash the RNA. Samples were centrifuged at 7,500 g for 5 min at 4 °C. The RNA 
isolation was finally achieved by discarding the supernatant and drying the pallet in room 
temperature for about 5 min. RNA was dissolved in 12 µl RNase-free water by passing 
them through a pipette. The amount of 2 µl RNA of each sample was taken for RNA 
concentration determination. The rest was stored at -80 °C for further reverse 
transcription. RNA concentration was determined by Nanodrop 2000.  
 Reverse transcription was accomplished with a SuperScript III first-strand synthesis 
kit (Invitrogen). The amount of 2 µg of each RNA sample was taken and balanced the 
volume of to 8 µl by RNase-free water for every sample, followed by addition of 1 µl 
oligo-dT primer and 1 µl dNTPs to each sample. The cDNA synthesis mix was prepared 
in a separate tube by mixing 2 µl of 10 × RT buffer, 4 µl of 25 mM MgCl2, 2 µl of 0.1 M 
DTT, 1 µl of RnaseOUT, and 1 µl of SuperScript III RT (10 µl total) for each sample. The 
prepared mix was kept on ice. The samples (RNA + primer + dNTPs) were projected 
onto the thermal plate of PCR machine (Eppendorf RealPlex2). The program was set as 
65 °C for 5 min, pause, 50 °C for 50 min, 85 °C for 5 min, pause, 37 °C for 20 min, and 
hold at 4 °C. After reverse transcription program started, the samples were taken out at 
the first pause and placed on ice for at least 1 min. Prepared cDNA synthesis mix (10 µl) 
was added to each sample. At the second pause, 1 µl of RNase H was provided for each 
sample.  
 The resulting cDNA was next used for PCR amplification. Primer sequences for Kv1.1 
were forward GGAGCGCCCCCTACCCGAGAAG, reverse 
GGTGAATGGTGCCCGTGAAGTCCT, product length 191 base pairs (bp); for Kv2.1, 
forward TGGAGAAGCCCAACTCATC, reverse  CAATGGTGGAGAGGACATG, product 
length 78bp; for Kv4.2, forward GCCGCAGCGCCTAGTCGTTACC, reverse 
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TGATAGCCATTGTGAGGGAAAAGAGCA, product length 262 bp; and for GAPDH, 
forward TCAAGAAGGTGGTGAAGCAG, reverse AGGTGGAAGAATGGGAGTTG, 
product length 126 bp. PCR cycles were performed as follows: initial 5 min at 95°C, then 
30 cycles of 95°C (15 s), 55°C (30 s), and 72°C (45 s), followed by 10 min at 72°C  for 
further extension. 
2.8. Immunoblotting 
Briefly, pre-treated neurons were washed twice with ice-cold PBS and total proteins 
were extracted using RIPA (Sigma- Aldrich).  
2.8.1. Total protein extraction  
The whole cell lysates were prepared in RIPA buffer (BioRad, Hercules, CA) while 
tissue was lysed in tissue extraction reagent (Invitrogen). In details, following 
experimental treatments, neurons were washed twice with ice-cold PBS and then PBS 
was aspirated. RIPA buffer supplemented with protease inhibitor (Sigma) was added 
(150 µl) to each well of 6-well plate. Cells were detached by scraping the well bottom 
and gently transferred into a microcentrifuge tube. Lysate was then projected to a 
freeze-thaw cycle for complete lysis, and then centrifuged at 10,000 r.p.m. for 10 min 
and supernatant was collected to a fresh tube. Next, 20 µl of each sample was taken out 
for protein concentration determination. A quarter of the sample volume of 5 × loading 
buffer was added to protein samples. Protein samples were denatured by boiling water 
for 7 min, and stored in -20 °C for western blotting. 
5 × loading buffer consisted of 0.25% Bromophenol blue, 0.5 M  dithiothreitol, 50% 
glycerol, 10% sodium dodecyl sulfate, and 0.25 M Tris-Cl (pH 6.8). 
2.8.2. Protein concentration determination 
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The BCA protein assay kit (ThermoFisher Scientific, Waltham, MA) was employed to 
quantify protein concentration. BCA working reagent was prepared by mixing 50 parts of 
BCA Reagent A with 1 part of BCA reagent B. The needed total volume of working 
reagent was determined by the following equation: (number of standards + number of 
unknowns) × (number of replicates) × 100 µl = total volume of working reagent required. 
Standards were prepared by diluting 2 mg/ml albumin ampules in working reagent to 
200, 100, 50, 25, 12.5 µg/ml. Then 100 µl of each standard was put into a 96-well plate. 
At separate wells, 100 µl of working reagent only was placed as zero. Next, 10 µl of 
each unknown samples was diluted to 90 µl working reagent. Every standard and 
sample was duplicated. After all samples prepared, the plate was incubated in 37 °C for 
30 min. The plate was then placed in a plate reader and the absorbance of all the 
samples were measured with the testing wavelength at 560 nm. 
 Standard curve was made by plotting the average Blank-corrected measurement for 
each albumin standard versus its concentration in µg/ml. The standard curve was used 
to determine the protein concentration of each unknown sample. The volume for 15 µg 
protein of each sample was calculated and then the denatured samples were projected 
to Western blotting. 
2.8.3. Western blotting 
   Solutions of 10 × Tris/glycine buffer, 10 × Tris/glycine/SDS buffer, 10% SDS, and 30% 
Acrylamide/bis solution were all purchased from Bio-Rad. The 10 × TBS (Tris-buffered 
saline, 1 liter) was prepared by dissolving 24.2 g Tris base, 80 g NaCl in distilled water, 
and adjust pH to 7.6 with HCl. Washing buffer was prepared by diluting 1 ml 100% 
Tween-20 to 1 liter 1× TBS (TBST).  
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 Proteins were firstly separated by electrophoresis depending on the molecular weight. 
In details, 15 µg protein of each sample was loaded onto 10% SDS-polyacrylamide gels. 
Electrophoresis was run under 70 mV constant voltage and switched to 110 mV when 
samples enter lower separating gel. Electrophoresis was stopped when the 
Bromophenol blue reached the bottom edge of SDS-polyacrylamide gel. 
After electrophoresis, proteins were transferred from gel to a polyvinylidene difuoride 
(PVDF) membrane by 100 mV constant voltage in 1 × Tris/glycine/SDS buffer containing 
20% methanol for 70 min at 4 °C. The PVDF membrane was then blocked in 5% non-fat 
milk in TBS for 1 h in room temperature. Following blocking, membranes were incubated 
at 4 °C overnight in primary antibodies including rabbit polyclonal KV1.1 (1.500), mouse 
monoclonal KV2.1,(1:500) (Abcam Inc. Cambridge, MA), rabbit anti-KV4.2 (1:200, 
CHENICON International, Inc. ), anti-mouse β-actin (1:5,000), or anti-rabbit GAPDH 
(1:5,000) to detect Kv1.1, Kv2.1, Kv4.2, GAPDH, and β-actin protein. Afterwards, 
membranes were washed in TBS with 0.2% Tween (TBS-T) and incubated with either 
HRP-conjugated onto rabbit or anti-mouse secondary antibody (1:10,000, Haacson 
ImmunoResearch Laboratories, West Grove, PA) for 1 h at room temperature. Finally, 
membranes were washed and visualized by Pierce ECL Western Blotting Substrate 
(Thermo Scientific, Rockford, IL). Band densities captured by ImageJ. 
2.9. Statistical analyses 
All data were expressed as mean ± S.E.M. unless otherwise indicated.  Statistical 
analyses were performed by one-way ANOVA or two-tailed t test.  The difference 





3.1. gp120-induced neuronal toxicity was protected by pGSN 
Neuron is not the primary cell type HIV-1 target at in brain [218]. However, viral 
envelope glycoprotein gp120 has been demonstrated to induce neuronal apoptosis in 
cell cultures [234, 235]. Further, while pGSN has been shown to be protective against 
excitotoxic insults [241], it is detected at significantly lower levels in the CSF of HIV-1-
infected individuals who exhibit neurocognitive disorder [243, 254]. In light of these 
findings, we sought to determine the effect of pGSN on gp120-induced neuronal toxicity. 
First, rat cortical neuronal cultures were prepared and incubated for 24 h with varying 
concentrations of gp120 (0-1000 pM). Neuronal viability was then assessed by MTT 
assay and found to diminish significantly at gp120 concentrations above 250 pM (Fig. 
23A). Given the nearly 40% loss of viability at concentrations of and greater than 500 pM, 
the concentration of 500pM was utilized in neurotoxicity experiments. Next, neuronal 
cultures were treated for 24 h with 500 pM gp120 and different concentrations of pGSN 
(0-2500 ng/ml). pGSN was found to be significantly protective against gp120-induced 




Figure 22.GSN protection of gp120-induced neuronal damage. Panel A, Dose-
dependent toxicity of gp120 on cortical neurons. Exposure of neuronal cells to gp120 at 
and greater than 500 pM resulted in maximal reduction in cell viability. Panel B, neurons 
were treated with different concentrations of GSN or with 500 pM gp120 for 24 h. pGSN 
protected neurons from gp120-induced damage at 2.5 µg/ml. Heat (boiled) inactivated 
pGSN (indicated by a symbol §, the same as in other figures of Chapter 4) failed to 
produce protective effect. Data represent means ± S.E.M. from at least 5 independent 
experiments and expressed as % of control. * p < .05 vs. control, ** p < .01 vs. control; # 




3.2. pGSN attenuation of gp120 increase of outward K+ current 
It has been shown that activation of neuronal Kv channels is involved in neuronal 
dysfunction and apoptosis [139, 255]. In HIV-1 infection, secreted cellular and viral 
products can increase Kv channel activity, leading to neuronal dysfunction and cognitive 
deficits [145]. Specifically, previous experiments in our laboratory have demonstrated 
gp120 can induce apoptosis by enhancing 4-AP-sensitive IA current via PKC signaling 
[143]. Given the prominent role of Kv channels in mediating neuronal damage, coupled 
with the protective effects of pGSN against gp120-induced neurotoxicity observed here, 
we further sought to determine if the protection provided by pGSN occurs via alterations 
in Kv channel activity. First, rat cortical neuron cultures were prepared and treated with 
gp120 at concentrations of 50 pM or 100 pM for 24 h. Whole-cell outward K+ currents 
were then recorded. As shown in Figure 23A, gp120 produced an increase of outward K+ 
currents. Further analyses revealed that gp120 significantly (p < .01) increased both 
instantaneous and steady-state outward K+ currents at a concentration of 100 pM (Fig. 
23B).  Next, we examined effects of pGSN on its blockade of gp120 increase of neuronal 
outward K+ currents. Neuronal cultures were treated for 24 h with either 100 pM gp120 
alone or with gp120 (100 pM) and different concentrations of pGSN (0, 5, 50, 500 ng/ml).  
As expected, gp120 enhanced both instantaneous and steady-state outward K+ currents 
(Fig. 24).  Treatment with pGSN reduced gp120-associated increase of outward K+ 
currents, with a significant (p < .01) reduction of the steady-state outward K+ current at a 
concentration of 500 ng/ml (Fig. 24B). Application of pGSN alone at concentrations of 5, 
50 and 500 ng/ml (data not shown) or heat-inactivated pGSN (500 ng/ml, Fig. 24B) had 
no significant effects on gp120 increase of outward K+ currents. These results indicate 




Figure 23. Gp120 increase of outward K+ currents. Cultures were treated without or 
with 50 pM or 100 pM gp120 respectively for 24 h. Panel A, representative current traces 
evoked by voltage protocol (upper left, not proportional to the current traces in duration) 
from three different neurons treated without (Ctrl) or with 50 pM, 100 pM gp120 
respectively for 24 h. Note gp120 at 100 pM increased outward K+ currents. Current 
amplification was measured at the peak for instantaneous current and at 300 ms for 
steady-state current. Panel B, instantaneous and steady-state current densities 
measured at +80 mV from groups of neurons treated without (Ctrl, n = 15) or with 50 pM 
gp120 (n = 13), 100 pM gp120 (n = 18). Note that gp120 increased both instantaneous 
and steady-state outward K+ currents at 100 pM. ** p < 0.01 vs. control.  
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Figure 24. pGSN decrease of gp120 enhancement of neuronal outward K+ currents. 
Panel A, representative current traces recorded from6 different neurons treated with 
gp120 (100 pM) alone, or gp120 (100 pM) and different concentrations of pGSN (5, 50, 
500, 500§), or untreated control. Whole-cell currents were generated by voltage steps 
from the holding potential of −80 mV to +80 mV in increments of 20 mV. Both 
instantaneous and steady-state outward K+ currents were measured and current 
densities were calculated and displayed in Panel B. pGSN only inhibited gp120-induced 
steady-state K+ current. In contrast, heat denatured pGSN lose such an inhibitory ability. 




3.3. Gp120 enhancement of TEA-sensitive IK was inhibited by pGSN. 
Two components of outward K+ currents recorded TEA-sensitive IK and 4-AP-
sensitive IA were recorded in neurons. Previous studies indicate certain outward K
+ 
currents may be more involved in apoptosis [223]. In order to determine the specific 
outward K+ currents enhanced by exposure to gp120 and attenuated by treatment with 
pGSN, whole-cell recordings were repeated in the presence of 4-AP (5 mM) or TEA (40 
mM).  As seen in Figure 25, gp120 (100 pM) augmented both 4-AP-sensitive IA and 
TEA-sensitive IK (Fig. 25A), while only TEA-sensitive IK was suppressed with GSN 
treatment (Figs. 25A and 25C).  Application of pGSN (500 ng/ml) alone did not affect the 





Figure 25. pGSN inhibited gp120 enhancement of TEA-sensitive IK, but not 4-AP-
sensitive IA. Panel A shows representative total (upper), 4-AP-sensitive (middle) and 
TEA-sensitive (lower) outward K+ currents recorded from neurons treated with gp120 
(100 pM), gp120 (100 pM) + pGSN (500 ng/ml), pGSN (500 ng/ml) or untreated controls 
(Ctrl). Panel B and C are current density-voltage relationships, illustrating GSN inhibition 
of TEA-sensitive IK. pGSN alone did not affect either the 4-AP- or TEA-sensitive outward 
K+ currents (P < .05). For each type of outward K+ currents, 25 neurons were recorded in 




3.4. Involvement of Kv2.1 in pGSN attenuation of gp120-induced IK 
enhancement  
The predominant subtypes of Kv channels reported that involve in neuronal injury 
and apoptosis are Kv1 [253, 256], Kv4 [257], and Kv2 [152]. In neurons, Kv1.1 and 
Kv4.2 are the principal components of IA, while Kv2.1 is responsible for IK [258]. Given 
our immediate findings, we postulated Kv2.1 channels to be the predominant mediator of 
the neuroprotection provided by pGSN. To test this hypothesis, we utilized the Kv2.1-
specific inhibitor, Guangxitoxin (GxTx) [259, 260]. Control, gp120, and gp120 + pGSN 
groups were again prepared as described above. During the recordings, IK was isolated 
by the addition of 4-AP (5 mM) to the bath solution and its Kv2.1 contribution suppressed 
by application of GxTx (50 nM). The addition of GxTx to the control group suppressed 
nearly 40% of the IK component (Fig. 26B), demonstrating the contribution of Kv2.1 
channels to the delayed outward K+ current in these neurons. More importantly, the 
previously observed enhancements in IK induced by exposure to gp120 were absent in 
the presence of GxTx, indicating the increase was comprised of current through Kv2.1 
channels (Fig. 26). Lastly, the gp120-enhanced IK attenuated by co-incubation with GSN 
was not further inhibited by the addition of GxTx, allowing us to infer that both may affect 





Figure. 26. Involvement of Kv2.1 in pGSN inhibition of gp120 enhancement of TEA-
sensitive IK. Cultures were treated for 24 h with 100 pM gp120, 500 ng/ml pGSN or 
gp120 and pGSN. Panel A, representative TEA sensitive currents recorded from 
neurons with treatments indicated. TEA sensitive IK was recorded in the presence of 4-
AP (5 mM) alone or 4-AP and GxTx (50 nM). Note that GxTx, a specific Kv2.1 channel 
blocker, abolished gp120 enhancement of the TEA sensitive IK. Panel B, a summary bar 
graph of current densities (n = 25) showing GxTx inhibition of gp120 increase of TEA 
sensitive K+ currents generated by a voltage step from −80 to +80 mV and GxTx per se 




3.5. Gp120-induced TEA sensitive IK inactivation curve shift was blocked by 
pGSN 
The causative factors resultant in alterations of the current amplitudes of ion 
channels are potentially: regulation of channel expression, promotion of channel 
translocation, or modification of channel activation. To further determine the mechanism 
of gp120 enhancement of IK and its inhibition by pGSN, we next investigated the impact 
of gp120 and pGSN on Kv channel activation and inactivation properties. Rat cortical 
neuron cultures were first prepared for whole-cell recordings as described previously. IK 
current was then isolated for recording by the addition of 4-AP to the bath solution. To 
characterize the steady-state inactivation behavior of IK, 400 ms pre-conditioning pulses 
were applied to step the membrane potential from -120 mV to +40 mV in 10 mV 
increments, followed by a 200 ms testing at +40 mV. I-V curves were then plotted and fit 
using the Boltzmann equation (I/Imax=1/{1+exp[(V-V1/2)/k]}) to yield the inactivation curve 
(Fig. 27A, 27B). Similarly, the activation curve was generated by applying 400 ms 
depolarizing pulses to step the membrane potential from 120 to +40 mV in 20 mV 
increments and fitting the I-V data using the Boltzmann equation (G/Gmax=1-1/{1+exp[(V-
V1/2)]/k} (Fig. 27A, 27B). Having established the IK inactivation and activation 
tendencies under control conditions, cells were then perfused for 10 min with either 
gp120 (200 pM) or gp120 (200 pM) + pGSN (1000 ng/ml) and recorded using the 
identical protocol. Exposure to gp120 resulted in a significant right-ward shift of the 
steady-state IK inactivation curve and a slight left-ward shift of the activation curve, 
reflecting a greater open channel probability at a given voltage. Further, the gp120-
induced depolarizing shift in the inactivation curve was counteracted by pGSN co-





Figure 27. pGSN blockage of gp120-mediated outward K+ current inactivation shift. 
Panel A, the original current traces before and after the perfusion of 200 pM gp120 or 
200 pM gp120 and 1 µg/ml GSN showed as above, and currents of treatment induced 
after recording 10 min in the same cell as control. Normalized data points were fitted 
with the Boltzmann equation: I/Imax=1/{1+exp[(V-V1/2)/k]} and G/Gmax=1-1/{1+exp[(V-
V1/2)]/k}. Each point represents the mean ± S.E.M., n = 5. Panel B, for inactivation, in the 
presence of gp120, V1/2 was -38.51 mV compared with -51.64 mV in Control (Ctrl); and 
V1/2 was -52.61 mV for gp120 + GSN compared with -51.14 mV for Control. Panel C, for 
activation, V1/2 values for TEA sensitive currents were -41.93 mV in gp120 and -30.59 in 
Control; and -31.13 mV in Gp120 + GSN group compared with -30.32 mV in Control 
group. Thus, gp120 caused depolarizing shifts of the steady-state inactivation of TEA 




3.6. pGSN inhibition of gp120-caused Kv2.1 protein expression up-
regulation 
To further characterize the mechanism of gp120-enhanced IK and its reduction by 
GSN, we next examined alterations in Kv channel expression related to exposure to 
gp120 and pGSN. Rat cortical neurons were first incubated for 24 h with gp120 (500 pM), 
pGSN (2500 ng/ml), or gp120 and pGSN combined. The mRNA and protein levels of the 
Kv channels responsible for outward K+ current in neurons, Kv1.1, Kv2.1, and Kv4.2, 
were then assessed by RT-PCR and Western blot. As expected, application of pGSN 
alone did not affect Kv channel mRNA expression. In comparison to control, exposure to 
gp120 increased the mRNA expression of all three channel subtypes, with Kv1.1 mRNA 
expression reaching statistical significance (Fig. 28A). Consistent with our 
electrophysiological findings, co-incubation with pGSN attenuated gp120-enhanced 
expression of Kv2.1 channel mRNA, but did not affect the elevated expression of Kv1.1 
and Kv4.2 mRNA (Fig. 28A). Similarly, channel protein levels were unaffected by the 
application of pGSN alone, but were significantly increased for all three Kv channel 
subtypes in the gp120 exposed group (Fig. 28B). Again in agreement with our 
electrophysiological studies, co-incubation with pGSN was found to prevent gp120-
induced elevations in Kv2.1 protein level, without inhibiting similar increases in the 





Figure 28. pGSN inhibition of gp120-induced Kv2.1 channel expression. Neuronal 
cultures were treated with 500 pM gp120 with or without 2.5 μg/ml pGSN for 24 h. Band 
density was analyzed by Image J and normalized by internal control. Data represents 
means ± S.E.M. from 3 independent experiments. Panel A, gp120 increased the levels 
of Kv1.1 mRNA expression (p < .05). Although increased levels of Kv2.1 and Kv4.2 
mRNA expression did not reach the statistical significance (p < .05 compare to control), 
the expression levels of Kv2.1 mRNA was down-regulated by pGSN compared to gp120 
group (p < .05). Panel B, gp120 significantly increased the levels of Kv1.1, Kv2.1 and 
Kv4.2 channel protein expression (p < .01). pGSN significantly reduced only Kv2.1 
channel protein expression (p < .01). pGSN alone did not alter the expression levels of 
Kv channels. * p < .05 vs. control; ** p < .01 vs. control; # p < .05 vs. gp120 group; ## p 
<.01 vs. gp120 group. 
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3.7. pGSN protected neurons from gp120-induced damage via Kv2.1  
By giving that pGSN mitigates gp120-induced neuronal viability decrease, prevents 
gp120-indued alterations in IK inactivation properties and Kv2.1 channel expression, we 
then determined the involvement of Kv2.1 in gp120-associated neuronal apoptosis to 
establish the neuroprotective activity of pGSN in gp120-associated neuronal injury by 
Kv2.1. We performed studies on neuronal apoptosis and viability using gp120, pGSN, 
and the Kv2.1-specific inhibitor GxTx. First, rat cortical neuron cultures were incubated 
for 24 h with gp120 (500 pM), pGSN (2500 ng/ml), GxTx (12.5 or 25 nM), gp120 + pGSN, 
or gp120 + GxTx. Neuronal apoptosis was then assessed by Tunel stain and neuronal 
viability by MTT assay. In comparison to control, neuronal viability was reduced by 33% 
in cultures incubated with gp120 (500 pM), while co-incubation treatment with pGSN 
(2500 ng/ml), GxTx (12.5 nM), or GxTx (25 nM) restored neuronal viability to 88.5%, 
79.0%, and 83.0%, respectively (Fig. 28A). Similarly, exposure to gp120 resulted in a 5-
fold increase in neuronal apoptosis, which was attenuated by GSN and GxTx in a dose-







Figure 29. pGSN attenuated gp120-induced neuronal damage via Kv2.1. Neurons 
were exposed to gp120 (500 pM), pGSN (2.5 μg/ml), gp120 (500 pM) and pGSN (2.5 
μg/ml), or heat inactivated pGSN (2.5 μg/ml) in the presence or absence co-incubated 
GxTx (12.5 or 25 nM) for 24 h. Panel A, cell viability determined by MTT assay exhibited 
that gp120 exposure reduced cell viability (p < .01 compare to Control), which was 
attenuated by GSN or GxTx. Heat-inactivated pGSN (§) showed no protective effect. 
pGSN or GxTx alone did not alter cell viability. Panel B, Left panel shows Tunel staining 
results as a measure of apoptosis, with cell nuclei visualized using Dapi stain. 10 visual 
fields were analyzed for each of three independent experiments. Gp120 induced 
neuronal apoptosis that was attenuated by either pGSN or GxTx. These data suggest 
that pGSN protects against gp120-induced neuronal damage via Kv2.1. ** p <.01 vs. 





In the present study, we showed that the HIV-1 envelope protein gp120 induced 
cortical neuron dysfunction and apoptosis via Kv2.1. There are two novel findings: first, 
pGSN performs neuroprotection in gp120-induced neuronal impairments; second, Kv2.1 
is involved in gp120-mediated neurotoxicity and pGSN protection. 
The main proposed mechanisms of HIV-infection and HAND are toxic substances 
released from infected macrophages and microglia, including viral products such as 
gp120, causing neuronal dysfunction and apoptosis [261-264]. Given the requirement for 
K+ efflux in processes of programmed cell death [84], our recent research has focused 
on the role of Kv channelopathies in HAND pathology [143, 144, 252, 265]. Based on 
research demonstrating the protective effect of GSN against Ca2+-mediated excitotoxicity 
[241, 242], combined with proteomic studies indicating the level of pGSN is decreased in 
the CSF of HIV-infected individuals with cognitive impairment [243], here we delve into 
the connection between gp120, pGSN, and Kv channels. Presently we show two novel 
findings: first, the induction of neuronal injury by HIV-1 envelope protein gp120 entails 
enhanced IK through Kv2.1 channels, and second, pGSN provides neuroprotection 
against gp120 by preventing the modification of channel expression and inactivation 
properties underlying IK enhancement.  
Previous research into the pathways of HAND neuropathogenesis has focused 
primarily on infected and/or activated mononuclear phagocyte releasing neurotoxins 
including, but not limited to, arachidonic acid, platelet-activation factor, free radicals, 
glutamate, quinolinate, cysteine, cytokines, amines and viral proteins (Tat and gp120).  
Although neurons do not express CD4 receptor, a principal receptor for HIV-1 entry into 
host cells, they do express the chemokine and HIV-1 infection co-receptors CXCR4 and 
CCR5. Along with NMDA receptors, these receptors can be pathologically activated by 
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aforementioned neurotoxins and viral products such as gp120, leading to alterations in 
signal transduction, excitotoxic influx of Ca2+, neuronal dysfunction, and eventual 
apoptosis [234-236]. While the process of apoptosis is now generally accepted to involve 
excess K+ efflux regardless of cell type or initiating stimuli [84, 223], reports of Kv 
channel contribution to gp120-related neuronal damage are rare. In a previous 
publication, our data suggested gp120 may induce caspase-3 dependent neuronal 
apoptosis by enhancing IA via CXCR4-PKC signaling [143]. Results from the present 
experiment indicate gp120 exposure also leads to amplification of an IK current (Fig. 25), 
which was found to be susceptible to Kv2.1-specific inhibition (Fig. 26), by provoking a 
depolarizing shift in IK channel inactivation properties (Fig. 27) and an upregulation of 
Kv2.1 channel expression (Fig. 28). Furthermore, the significance of this increased 
Kv2.1 channel activity was demonstrated by MTT assay and Tunel staining assessments 
of neuronal health, which established that gp120-induced neuronal damage could be 
alleviated by Kv2.1-specific inhibition (Fig. 28). These findings are consistent with 
research on hippocampal neurons demonstrating upregulation of Kv2.1 to be essential 
to the induction of apoptosis under conditions of excess glutamate, the natural ligand of 
NMDAR [256]. In a similar experiment, glutamate was found to act through NMDAR to 
induce dephosphorylation of Kv2.1 channels and thereby alter channel function [266]. 
While HIV-1 infection of the CNS is associated with excess glutamate release and 
impaired uptake [267], gp120 is also known to trigger NMDAR-mediated neuronal death 
and thus may initiate similar apoptotic cascades [267, 268]. 
Neuron loss is a common feature observed in many neurodegenerative diseases. In 
order to better understand the cellular milieu in which this occurs and identify practical 
diagnostic markers, proteomic studies of CSF and plasma have been undertaken for 
numerous conditions including HAND. Proteomic analysis revealed that pGSN was 
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diminished in the CNS across varied conditions characterized by neuronal injury or 
dysfunction, including Alzheimer’s disease [245], multiple sclerosis [244], and epilepsy 
[246]. In HAND, pGSN is decreased in the CSF [243] and elevated in plasma [254]. 
Given the increased permeability of the blood brain barrier associated with HIV-1 
infection, the depletion of pGSN in the CSF may have significance for neuronal health 
and function, while the plasma abundance could be used as a diagnostic indicator [247]. 
It is important to note however, there are two isoforms of GSN, pGSN and cGSN, which 
may have different roles and be present in different concentrations [269]. HIV-infected 
macrophage have been found to secrete pGSN [270], which has been shown to be 
involved in further recruitment of macrophage to sites of injury [271] and is present in 
high concentration in the macrophage nodules of rhesus monkeys with SIV encephalitis 
[270]. While this might imply high CNS pGSN levels may be detrimental, several studies 
support the use of pGSN as a neuroprotective agent, for example in the treatment of 
Alzheimer’s disease [245], multiple sclerosis [250], and stroke [249, 251, 272]. 
Interestingly, in a primary cortical neuron model of ischemic neuronal injury, the 
enhanced expression of cGSN using the histone deacetylation inhibitor trichostatin A 
was found to provide neuroprotection [251], perhaps indicating a means for targeting the 
different isoforms for treatment. The mechanisms for these effects of GSN have yet to 
be definitively characterized.  
GSN is known to be regulated by micromolar Ca2+, among other factors, in its 
function of modulating filament disassembly of the actin cytoskeleton [273] as part of ion 
channel regulation, intracellular signaling, and apoptotic processes [274]. With regard to 
cell death, the presence of pGSN mitigates common features such as mitochondrial 
dysfunction, loss of membrane potential, and cytochrome C release [240]. Perhaps 
relevant here, however, is evidence that pGSN may reduce the cytosolic Ca2+ overload 
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resulting from exposure to excitotoxic stimuli by facilitating voltage-dependent Ca2+ 
channel (VDCC) and NMDA receptor channel rundown, while primary hippocampal 
neurons cultured from GSN-null mice and exposed to glutamate exhibited decreased 
actin filament depolymerization, increased Ca2+ influx, and amplified currents through 
VDCC and NMDA receptor channels [241, 242]. In one report, GSN even directly 
inhibited an HIV-1 viral protein Vpr from activating VDCC, thereby decreasing Ca2+ influx 
and reducing apoptosis [275]. Despite what is known the altered concentration of pGSN 
in HAND and its anti-apoptotic effects, no research has been yet undertaken to explore 
the link between gp120-related neuronal damage, apoptotic Kv channel activity, and 
pGSN. While GSN has been found to oppose gp120-mediated actin remodeling [276], 
here we sought to determine concretely if pGSN might provide neuroprotective activity 
against gp120 exposure and to make clear the pathways involved. In addition, one 
report found the addition of GSN actually increased K+ channel activity in human 
syncytiotrophoblasts [277].  In contrast, our results show that pGSN does indeed lessen 
apoptosis in cortical neurons exposed to gp120 (Fig. 22) by suppressing the gp120-
associated upregulation of Kv2.1 expression (Fig. 28) and depolarizing shift of IK 
inactivation properties (Fig. 27), thereby inhibiting gp120-enhanced IK (Figs. 24 and 25) 
through Kv2.1 channels (Fig. 26), ultimately resulting in a reduction of gp120-induced 
Kv2.1-dependent apoptosis (Fig. 28).  Considered with research conducted elsewhere 
and previously described, a tentative global picture emerges of the relationship between 
HIV-1 gp120 exposure, apoptotic K+ efflux through Kv2.1 channels, and the protective 
role of pGSN in suppressing gp120-mediated enhancement of apoptotic Kv2.1 currents.  
Although the present study demonstrates that pGSN protects gp120-induced 
neuronal injury via inhibition of gp120 enhancement of Kv2.1 expression and Kv2.1 
current in rat cortical neuronal cultures, the exact mechanism underlying pGSN-
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mediated protection is not yet clear, nor is the site(s) of action – intracellular and/or 
extracellular?  A previous study from our laboratory showed gp120 interacts with 
intracellular signaling, resulting in an enhancement of outward K+ currents and 
consequent neuronal injury [143].  In another study carried out on Jurkat T cells, GSN 
was found to block the interaction between viral protein and voltage-gated ion channel.  
These results suggest that pGSN may inhibit the interaction between gp120 and Kv2.1 
leading to its neuroprotection.  Another possibility is pGSN blocks the interaction 
between gp120 and Kv2.1 channel as viral proteins were found to interact with ion 
channels [275]. In addition, pGSN may protect neurons through inhibition of gp120-
mediated activation of caspases since  gp120 has been shown to induce neuronal injury 
via activation of caspases [278, 279] and  GSN has been reported to, in complex with 
phosphatidylinositol 4, 5-biphosphate, inhibit caspase activity and retard apoptotic 
progression [280].  As to the site of pGSN action, it appears that pGSN acts 
extracellularly since pGSN inhibited gp120-induced shift of outward K+ current 
inactivation curve shortly after brief bath perfusion of pGSN (Fig. 27). Nevertheless, 
further studies are definitely needed to unravel the mechanisms of pGSN-mediated 
neuroprotection and the site(s) of action.  
It is worth pointing out that the effective concentrations for gp120 and GSN were 
different in studies measuring cell viability and K+ current, with higher concentrations for 
studying cell viability. This is because, in the same time window, higher concentrations 
were needed to produce changes in cell viability in comparison with the concentrations 
used to generate alterations of membrane ionic currents conducted by ion channels. 
Importantly, it is difficult to form gigaohm seal and record whole-cell current from injured 
cells.  For these reasons, different concentrations of gp120 and GSN were employed in 
the present study.  
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In summarizing the present experiment, several principal findings bear mention. First, 
exposure to gp120 causes neuronal injury by amplifying neuronal IK current via 
modification of Kv2.1 channel expression and activation. Second, the presence of pGSN 
mitigates gp120-induced apoptosis by inhibiting gp120-related enhancements of Kv2.1 
channel activity. Collectively, these experimental results serve to further define the link 
between HAND pathogenesis and Kv channelopathies [265], while at the same time 
supporting a potentially neuroprotective role for pGSN in the treatment of HAND and 
other neurodegenerative diseases.  
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Milder forms of HAND remain prevalent in the era of cART. Given that HIV-1 proteins 
and toxic factors released from infected cells persist in brain while viral load is well 
controlled in blood, there are remaining uncertain mechanisms of viral protein 
neurotoxicity and increasing interests in myelin sheath loss and WM damage in 
neuroHIV brain. Presently we show six novel findings: 1) HIV-1 Tat increases KV1.3 
currents in oligodendrocytes by interacting with KV1.3 channel and interrupting channel 
phosphorylating regulation; 2) Continuous increased K+ efflux through KV1.3 leads to 
OPC and oligodendrocyte apoptosis and loss of cell viability; 3) Tat exposure decreases 
MBP expression in highly purified primary rat oligodendrocyte cultures and, disturbs 
myelin structures in corpus callosum and stratum of cultured brain slices; 4) Tat 
treatment hinders OPC maturation in primary OPC culture; 5) In primary neuronal culture, 
the induction of neuronal injury by HIV-1 envelope protein gp120 entails enhanced IK 
through Kv2.1 channels; 6) pGSN provides neuroprotection against gp120 by preventing 
the modification of channel expression and inactivation properties underlying IK 
enhancement. Collectively, these experimental results serve to further define the link 
between HAND pathogenesis and KV channelopathies, while at the same time 
supporting a protective role of KV1.3 blockade for OPC/oligodendrocytes protection and 
neuroprotective role of pGSN in the treatment of HAND and other 
demyelination/neurodegenerative disease.  
The axon damage and myelin injury are still challenging in therapeutic strategy of 
HAND. The ways on the regulation of oligodendrocyte lineage cell development are well-
established including the extracellular pathways, cell to cell contact, and intracellular 
pathways. The strategies for promoting axonal remyelination have been introduced 
especially in those demyelinating disease like multiple sclerosis, of which KV channel is 
an attractive target. It is anticipated that those strategies for promoting axonal 
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remyelination in other neurodegenerative disorders can be applied for HIV-1-associated 
oligodendrocyte/myelin injury; thought studies are needed to elucidate the underlying 
mechanisms for HIV-1-associated brain WM damage. However, further studies on 
understanding the mechanisms underlying HIV-1-associated oligodendrocyte/myelin 
injury may be hampered by the following potential difficulties. First, oligodendrocytes 
share many common extracellular signals and intracellular signaling pathways with 
neurons, the proposed “inside-out” and “outside-in” mechanisms are indistinguishable 
[65]. Second, the pro-proliferation signals for OPC are generally anti-differentiation. This 
will be a significant challenge to specify the certain time window to access proper 
remyelination in vivo. Overall, enhancing remyelination will be an important therapeutic 
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